



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GENERAL APPROACH TO LOWER URINARY TRACT
DYSFUNCTION IN MS
Problems may include storage (overactive bladder) symptoms
such as daytime or night-time frequency, urgency of micturi-
tion, incontinence and/or symptoms of ineffective voiding such
as difficulty in passing urine, poor stream and double voiding
(fig 1), and both must be managed in order to optimise
treatment. Investigations and management advice should be
appropriate for the patient’s current needs and level of
disability.
Recommendation
c Each person with MS who complains of lower urinary tract
symptoms should be assessed by a suitably trained health
care professional who is knowledgeable about MS and its
effects on lower urinary tract function. Patients should be
periodically reviewed for new or changing lower urinary
tract symptoms (grade D).
INVESTIGATIONS FOR PLANNING MANAGEMENT
Urine testing
Combined rapid tests of urine, ‘‘dipstick’’ test, using reagent
strips for urinalysis, is advisable for all patients with MS
presenting with new bladder symptoms (fig 3). Negative
predictive value for excluding urinary tract infection (UTI) is
excellent (.98%) but the positive predictive value for confirm-
ing UTI is only 50%.13 Haematuria should always be fully
investigated (see NICE recommendations on improving out-
comes in urological cancers)—all patients with visible haema-
turia and patients more than 50 years of age with microscopic
haematuria should be referred for further investigation.
Measurement of the post micturition residual volume
The post micturition residual urine should be measured as part
of the initial assessment and preferably before antimuscarinic
treatment is started (see fig 3). Furthermore, if there is any
reason to suspect a patient already established on treatment has
developed incomplete emptying (either from history or from
their failure to respond to antimuscarinics), or has had more
than one confirmed or two suspected episodes of urinary tract
infections in a period of 1 year, the post micturition residual
volume should be measured by ultrasound or, alternatively, in-
out catheterisation, if the equipment is not available.
In the majority of cases, this single investigation provides the
necessary information on which to base effective management.
Thus the recommended algorithm for management is shown in
fig 3.
Urodynamics
‘‘Urodynamics’’ (referring here to multichannel cystometry and
pressure/flow studies of voiding), with or without additional
synchronous fluoroscopic screening (video urodynamics), is
used in neuro-urological practice in order to plan management
of refractory symptoms or to identify patients at risk of future
complications, particularly upper urinary tract problems.
However, it should be noted that upper tract complications
are much less common in patients with MS than in spinal cord
injury. The reason for this is unknown and although urinary
sepsis, stone formation and upper tract dilatation may occur,
this is usually in the context of advanced disease (fig 2) and
rarely as a clinically silent, isolated problem. Any patient with
these complications is likely to have already been under the care
of a urologist and may well have a long term indwelling
catheter. Accordingly, as management is relatively unlikely to
be influenced, the likely benefit of urodynamic studies does not
invariably warrant the intrusive nature of the study and the
risks associated.
Typically, urodynamics are undertaken in patients with
refractory urinary urgency and incontinence who have not
responded to the measures summarised in fig 3. However, a
variety of other symptoms may need to be investigated using
urodynamics. For example, some women with MS will
complain of stress urinary incontinence; if surgical treatment
is being considered, full urodynamic evaluation, ideally by
videourodynamics, is necessary. This is because of the range of
mechanisms potentially contributing to bladder dysfunction in
women with MS, and the adverse outcome that can result if
voiding difficulties are not identified prior to surgery.
Thus the use of urodynamics is appropriate only in certain
situations where surgical or intravesical treatments are being
planned. This is at variance with guidelines published by a
French expert group who recommended urodynamic studies in
all MS patients with symptomatic lower urinary tract disease.14
The UK expert panel was of consensus opinion that the
management algorithm shown in fig 3 is generally applicable as
a firstline management strategy.
Recommendations
c ‘‘Dipstick’’ testing of the urine should be undertaken in
patients with new symptoms of bladder dysfunction (grade
D).
c Measurement of the post micturition residual volume by
abdominal ultrasound should be made in all patients with
bladder symptoms prior to treatment or if there is reason to
suspect that they have incomplete emptying (grade D).
Figure 3 Management algorithm for patients with multiple sclerosis
presenting with urinary tract symptoms. CISC, clean intermittent self-
catheterisation; PVR, post void residu l volume; UTI, urinary tract
infection.
Review
554 Postgrad Med J 2009;85:552–559. doi:10.1136/jnnp.2008.159178


















































There! is! little!doubt! that!LUTS!have!a!disproportionate! impact!on!QoL! for!patients!
and! their! carers! living! with! MS.! Data! from! large,! symptomMbased! surveys!
consistently! cite! LUTS!as!a!key!determinant!of!QoL,!with!an! impact! comparable! to!
that! of! loss! of! mobility! (54).! LUTS! may! also! interact! with! other! diseaseMrelated!



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No!pyuria!(zero!wbc)! 1116!(42%)! 141!(35%)! 582!(45%)! 1839!
Pyuria!1M9!wbc!μlM1! 875!(23%)! 97!(24%)! 173!(13%)! 1145!
Pyuria!≥10!wbc!μlM1! 643!(35%)! 168!(41%)! 537!(42%)! 1348!









Index$test!$ Sensitivity$(95%$CI)$ Specificity$(95%$CI)$ PPV$(95%$CI)$ NPV$(95%$CI)$

















Index$test$ Sensitivity$(95%$CI)$ Specificity$(95%$CI)$ PPV$(95%$CI)$ NPV$(95%$CI)$












Dipstick!negative! 729!(55)! 2235!(73)! 2964!!
Dipstick!positive! 585!(45)! 826!(27)! 1411!!











Dipstick!negative! 1566!(85%)! 937!(82%)! 840!(62%)! 3343!
Dipstick!≥!‘trace’! 273!(15%)! 208!(18%)! 508!(38%)! 989!





Index$test$ Sensitivity$(95%$CI)$ Specificity$(95%$CI)$ PPV$(95%$CI)$ NPV$(95%$CI)$










































































































































































































































































































































































































































































































































































































































































































































Demographic$data$ MS$patients$ Controls$ Test$statistic$ Significance$
Age$(years)$ 54.3!(sd=10.5)! 50.0!(sd=9.9)! t=1.47!(df=48)! p=0.15!





Gender$ MS$patients$(%)$ Controls$(%)$ Total$
Female! 26!(90)! 15!(72)! 41!
Male! 3!(10)! 6!(28)! 9!







Menopausal*$ MS$patients$(%)$ Controls$(%)$ Total$
Yes! 12!(46)! 7!(47)! 19!
No! 14!(54)! 8!(53)! 22!






Instrumented*$ MS$patients$(%)$ Controls$(%)$ Total$
Yes! 9!(31)! 7!(33)! 16!
No! 20!(69)! 14!(67)! 34!






Ethnicity$ MS$patients$(%)$ Controls$(%)$ Total$
Caucasian! 29!(100)! 14!(67)! 43!
Asian! 0!(0)! 4!(19)! 4!
AfroMCaribbean! 0!(0)! 3!(14)! 3!




























































































































































Culture$status$ MS$patients$(%)$ Controls$(%)$ Total$(%)$
Positive! 5!(17)! 2!(10)! 7!(14)!
Negative! 24!(83)! 19!(90)! 43!(86)!
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MSU!positive†! 6.33! 1.81! 0.00−7.35!
MSU!negative‡! 0.00! 2.58! 0.00−7.04!
*Characterised!by!culture!of!the!spun!urinary!sediment;!†Defined!as!the!pure!growth!of!a!
recognised!uropathogen!at!≥105!cfu!mlF1;!‡!Polymicrobial!culture!or!growth!below!105!cfu!mlF1;!
IQR=!interquartile!range.!
MSU$result!
Proportion$of$cultures$(%)$
No!growth*! Any!growth*!
MSU!positive†! 7.4! 92.6!
MSU!negative‡! 53.1! 46.9!
*Characterised!by!culture!of!the!spun!urinary!sediment;!†Defined!as!the!pure!growth!of!a!
recognised!uropathogen!at!≥105!cfu!mlF1;!‡!Polymicrobial!culture!or!growth!below!105!cfu!mlF1.!
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growth!of!2.75!log!cfu!mlM1!(95%!CI=2.47−3.02).!Significant!bacterial!infection!is!being!
missed!by!routine!culture!methods!with!fixed!diagnostic!thresholds.!
An!analysis!to!explore!the!relationships!between!bacterial!infection,!lower!urinary!
tract!function!and!urinary!symptoms!was!specified!in!the!study!protocol.!Only!
patient!data!was!included.!The!log!bacterial!count!was!defined!as!the!dependent!
variable!with!urgency!and!pain!scores,!ICIQMLUTS!and!ICIQMLUTSqol!questionnaire!
responses,!and!bladder!diary!data!entered!as!fixed!effects.!Model!assumptions!were!
checked!but!the!residuals!deviated!significantly!from!a!normal!distribution.!There!
was!also!evidence!of!multicollinearity!amongst!some!of!the!symptom!measures.!
Attempts!to!transform!the!data!did!not!yield!normally!distributed!model!residuals.!
These!violations!precluded!meaningful!interpretation!of!the!results!using!the!
statistical!model!specified!in!the!study!protocol.!!
!
An!alternative!statistical!approach!was!employed!in!which!symptom!measures!and!
bladder!diary!data!were!entered!as!dependent!variables!in!individual!models.!
Measures!of!urinary!infection,!inflammation!and!urothelial!distress!were!selected!as!
fixed!effects.!The!analysis!was!limited!to!the!urgency!score!and!bladder!diary!data!in!
order!to!constrain!model!multiplicity.!Urgency!is!the!hallmark!of!OAB,!and!although!
it!is!commonly!associated!with!urinary!frequency!and!incontinence,!urgency!remains!
the!principal!treatment!target!in!symptomatic!patients.!!
!
Urgency!scores,!24Mhour!urinary!frequency!and!incontinence!episodes,!and!mean!
voided!volume!were!selected!as!dependent!variables!in!individual!models.!Log!
bacterial!growth,!log!pyuria,!log!urinary!ILM6!and!log!urinary!ATP!were!selected!as!
fixed!effects.!The!influence!of!anticholinergic!drugs,!DDAVP!and!tricyclic!agents!(TCA)!
were!accounted!for!in!the!models.!Individuals!and!visits!were!selected!as!random!
effects.!The!model!residuals!were!normally!distributed!and!significant!
heteroscedasticity!was!excluded.!There!was!no!evidence!of!collinearity!amongst!the!
fixed!effect!variables.!
!
Only!pyuria!demonstrated!an!association!with!urinary!urgency!and!lower!urinary!
tract!function.!Bacterial!growth,!urinary!ILM6!and!urinary!ATP!did!not!influence!these!
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measures!in!any!of!the!models.!The!findings!were!independent!of!routine!culture!
status.!Increasing!pyuria!was!associated!with!worsening!urinary!urgency!and!
frequency,!and!a!reduction!in!voided!volume,!but!it!did!not!appear!to!influence!
incontinence!episodes!(Table$32).!Similarly,!the!use!of!anticholinergics,!DDAVP!or!
TCA!agents!did!not!mediate!any!significant!effects!in!this!group!of!patients.!
!
Table!32!Influence!of!log!pyuria!count!on!urinary!urgency,!urinary!frequency!and!
incontinence!episodes.!
!
Dependent$variable$$ Parameter$estimate*$$ Significance$
Urgency!score§! 0.70!(95%!CI=0.23−1.16;!t=3.01;!df=52.16)! p=0.004!
Voided!volume†! M38.99!(95%!CI=M59.57—18.42;!t=M3.78;!df=73.87)! p<0.0005!
24Mhr!frequency‡! 2.07!(95%!CI=1.17−2.98;!t=4.60;!df=54.44)! p<0.0005!
24Mhr!incontinence‡! 0.08!(95%!CI=M0.02−0.17;!t=1.60;!df=106.65)! p=0.112!
!
*Parameter!estimate:!Change!in!magnitude!of!dependent!variable!for!each!unit!increase!in!log!
pyuria;!§Urgency!score:!Whittington!urgency!score!(range!1F10);!†Voided!volume:!Expressed!in!
millilitres;!‡!Frequency!and!incontinence:!Episodes/24!hours.!
!
6.14 Discussion$
!
Protocol!deviations!were!frequent!but!minor.!Mistimed!or!missed!visits!were!
common,!but!there!were!no!concerns!that!such!deviations!affected!the!integrity!of!
the!data.!Patients!often!failed!to!submit!complete!bladder!diary!data,!although!all!
patients!completed!a!minimum!of!four!diaries,!as!demanded!by!the!protocol.!The!
study!groups!were!matched!at!baseline!and!the!demographic!and!diseaseMspecific!
variables!amongst!patients!who!left!the!study!were!similar!to!those!who!were!
included!in!the!analysis.!Statistical!power!was!maintained!well!within!the!constraints!
of!the!sample!size!calculation.!At!baseline!and!over!the!course!of!the!study,!there!
were!significant!differences!in!terms!of!bacterial!load!and!urothelial!inflammation!
amongst!patients!and!controls.!No!adverse!events!were!reported.!
!
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The!primary!analysis!demonstrated!that!amongst!patients,!the!emergence!of!pyuria!
was!associated!with!a!significant!increase!in!bacterial!growth.!This!relationship!was!
strengthened!by!the!results!of!the!secondary!analyses.!Rising!pyuria!was!associated!
with!increasing!bacterial!numbers.!When!the!analysis!was!confined!to!patients!with!
negative!routine!culture!the!results!were!very!similar.!These!findings!demonstrate!
that!the!relationship!between!urothelial!inflammation!and!bacterial!infection!is!not!
contingent!on!a!positive!routine!bacterial!culture.!
!
These!data!provide!evidence!that!the!emergence!of!pyuria!is!associated!with!higher!
bacterial!colony!counts.!As!the!magnitude!of!urothelial!inflammation!increases,!
bacterial!growth!increases.!However,!the!data!that!describe!the!interaction!between!
pyuria!and!bacteriuria!do!not!appear!to!demonstrate!a!simple!proportional!
relationship.!When!exploratory!models!were!generated!to!scrutinise!the!effect!of!
rising!bacterial!counts!on!pyuria!amongst!patients,!the!results!were!quite!different.!
Using!the!model!parameter!estimates!to!illustrate!these!findings,!an!increase!in!the!
leucocyte!count!of!1!log!wbc!μlM1!was!associated!with!a!mean!rise!in!bacterial!count!
of!approximately!2!log!cfu!mlM1.!By!contrast,!an!increase!in!the!bacterial!colony!count!
of!1!log!cfu!mlM1!was!associated!a!mean!increase!in!pyuria!of!0.2!log!wbc!μlM1.!
!
Pyuria!is!a!measure!of!urothelial!inflammation.!When!pyuria!increased!it!was!
accompanied!by!an!increase!in!colony!count.!These!data!demonstrate!that!in!the!
presence!of!lower!urinary!tract!inflammation,!increasing!inflammation!appears!to!be!
associated!with!increased!bacterial!numbers.!When!pyuria!was!selected!as!the!
dependent!variable!in!the!model,!significant!increases!in!bacterial!growth!were!
associated!with!only!very!small!increases!in!pyuria!expression.!
!
These!findings!hint!at!the!complex!relationship!between!bacterial!proliferation!and!
inflammation!in!the!lower!urinary!tract.!In!the!first!model,!increasing!urothelial!
inflammation!is!associated!with!increasing!bacterial!load.!Pyuria!reflects!stimulation!
of!the!innate!immune!system!and!implies!a!pathogenMhost!interaction.!In!the!second!
model,!rising!bacterial!colony!counts!have!a!comparatively!marginal!effect!on!
leucocyte!expression.!In!contrast!to!pyuria,!bacterial!load!is!not!synonymous!with!a!
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proportionate!microbeMhost!exchange.!Thus,!bacteria!appear!to!be!capable!of!
considerable!expansion!without!eliciting!a!significant!inflammatory!response.!!
!
When!the!analysis!was!confined!to!control!subjects!only,!increasing!pyuria!was!
associated!with!proportionately!greater!increases!in!bacterial!growth.!This!
association!was!comparable!to!the!parameter!estimate!generated!for!patients.!
Amongst!controls,!the!effect!of!rising!bacteriuria!on!pyuria!was!not!calculated!as!
model!assumptions!were!violated.!The!number!of!controls!demonstrating!pyuria!was!
very!small,!hampering!statistical!efforts!to!evaluate!this!relationship.!
!
These!data!seem!to!illustrate!that!although!bacteria!may!proliferate!without!
targeting!their!host,!once!an!incursion!on!the!host!is!established,!further!population!
expansion!leads!to!increased!tissue!damage!and!consequent!inflammation.!Whilst!
the!relationship!between!increased!bacterial!load!and!greater!host!damage!seems!
intuitive,!an!apparent!paradox!exists!in!that!marked!bacterial!expansion!may!occur!
without!the!host!being!attacked.!If!the!relationship!between!host!tissue!damage!and!
bacterial!proliferation!is!not!directly!proportional,!how!is!pathogenicity!controlled?!
Mounting!evidence!suggests!that!quorum!sensing!may!mediate!this!process.!
!
Quorum!sensing!is!a!term!that!describes!intercellular!communication!between!
bacteria.!This!process!allows!microbes!to!share!information!relating!population!
numbers!and!preferentially!modify!the!expression!of!individual!genes!in!response!to!
changes!in!cell!density!and!community!composition!(451).!Bacteria!are!microscopic!
organisms!and!individually!they!are!unable!to!manipulate!host!systems!through!
virulence!factors,!irrespective!of!the!potency!of!such!agents.!In!much!greater!
numbers,!the!concerted!efforts!of!large!bacterial!populations!may!be!able!to!gain!
advantage!over!their!host.!Advances!against!a!host,!for!example!to!secure!nutrients,!
are!associated!with!significant!risk!as!bacteria!face!immune!attack!and!energy!
expenditure.!If!an!attack!on!the!host!is!unsuccessful!it!may!threaten!the!survival!of!
the!community.!Quorum!sensing!appears!to!restrict!such!operations!by!constraining!
the!expression!of!genes!that!code!for!virulence!factors!until!a!critical!biomass!is!
! ! 223!
reached!(452).!Such!a!strategy!might!maximise!the!likelihood!of!a!successful!
interaction!with!the!host.!
!
Bacteria!communicate!by!releasing!small!molecules!termed!autoinducers!(AIs).!In!
conditions!of!low!cell!density,!these!AI!molecules!diffuse!without!detection!by!other!
microbes!as!they!have!no!‘near!neighbours’.!In!conditions!of!high!cell!density,!the!
local!concentration!of!AIs!may!become!extremely!high,!binding!to!receptors!on!
adjacent!cells!and!mediating!changes!in!gene!expression!(453).!In!addition,!the!
binding!of!AI!molecules!to!receptor!sites!further!stimulates!AI!production!by!
bacteria,!forming!a!positive!feedback!loop!(454).!These!insights!may!explain!the!
complex!relationship!between!bacterial!expansion!and!pyuria!noted!previously.!
Some!organisms!that!possess!potent!virulence!factors!might!successfully!initiate!an!
attack!on!their!host!at!lower!cell!densities!than!microbes!with!lesser!pathogenic!
potential.!Such!traits!would!be!propagated!within!a!population!by!natural!selection.!
!
Quorum!sensing!systems!are!not!only!for!intraMspecies!communication.!Bacteria!
from!different!species!and!genera!produce!universal!AI!signalling!molecules!that!
impart!information!about!the!population!density!of!other!organisms!(455,!456).!
Within!biofilms,!communication!between!different!cohabiting!bacteria!might!
facilitate!cooperation!within!these!communities!to!gain!a!survival!advantage!(457).!
Biofilm!formation!in!some!species!appears!to!be!contingent!on!an!intact!quorum!
sensing!system!(458,!459)!and!identical!bacterial!species!can!express!quite!different!
patterns!of!gene!expression!within!the!biofilm!itself!(460,!461).!In!contrast!to!a!
symbiotic!function,!some!microbes!utilise!information!from!quorum!sensing!systems!
to!neutralise!competing!populations.!The!production!of!antibiotics!to!kill!other!
bacteria,!or!manipulation!of!quorum!sensing!molecules!to!constrain!virulence!
amongst!competitors!has!been!described!(462M465).!
!
No!association!between!ATP!and!bacterial!load!was!demonstrated!but!increases!in!
urinary!ATP!were!associated!with!greater!pyuria.!Adenosine!triphosphate!belongs!to!
a!group!of!endogenous!molecules!that!are!released!in!response!to!tissue!damage!or!
physiological!stress.!These!molecules!are!known!as!dangerMassociated!molecular!
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patterns!(DAMPs)!and!are!able!to!trigger!or!augment!the!inflammatory!cascade!by!
activating!pattern!recognition!receptors!(PRRs)!on!innate!immune!target!cells.!These!
data!suggest!that!the!primary!source!of!purine!release!associated!with!lower!urinary!
tract!inflammation!might!be!host!cells!rather!than!bacteria.!
!
Urinary!ILM6!had!no!detectable!association!with!bacterial!growth.!Increased!urinary!
ILM6!secretion!has!been!demonstrated!in!prospective!studies!of!acute!UTI!(258)!but!
these!increases!were!not!evident!until!late!in!the!disease!course.!A!detectable!rise!in!
ILM6!was!observed!only!when!patients!manifest!dysuria!associated!with!frequency!or!
urgency,!pyuria!≥15!wbc!μlM1!and!bacteriuria!≥103!cfu!mlM1.!Whilst!there!are!some!
doubts!relating!to!the!sensitivity!of!the!ILM6!assay!used!in!that!study,!the!data!
generated!suggest!that!significant!urinary!ILM6!secretion!may!be!a!late!feature!in!
acute!cystitis,!perhaps!contingent!on!significant!immunostimulation!of!the!host.!!
!
Rising!levels!of!ILM6!were!associated!with!increasing!pyuria,!although!the!magnitude!
of!this!effect!was!small.!Although!ILM6!and!CXCLM8!may!be!induced!through!TLR!
activation!via!the!NFMκB!signalling!pathway,!these!molecules!have!distinct!roles.!
Whilst!pyuria!and!urinary!ILM6!are!indicative!of!urothelial!inflammation,!the!control!
of!leucocyte!chemotaxis!is!not!the!main!function!of!ILM6!which!is!a!key!mediator!of!
the!acute!phase!response!(249,!466).!Leucocyte!chemotaxis!is!primarily!mediated!
through!chemokines!such!as!the!prototypical!CXCLM8,!although!the!process!of!
leucocyte!migration!is!complex.!Vascular!transmigration!and!movement!to!sites!of!
inflammation!involves!numerous!other!chemoattractants,!lipid!mediators,!and!
DAMPs!(249).!InterleukinM6!augments!the!production!of!chemokines!such!as!CXCLM8!
and!other!mediators!of!vascular!adhesion!and!migration,!but!does!not!play!a!central!
role!in!neutrophil!trafficking!(466).!!
!
There!is!evidence!that!neutrophil!entry!into!the!lower!urinary!tract!may!occur!
independent!of!any!detectable!ILM6!response.!In!a!prospective!study,!23!patients!
with!a!history!of!recurrent!UTI!submitted!serial!CSU!samples!over!periods!extending!
to!18!months!(220).!In!an!analysis!confined!to!periods!when!the!patients!did!not!
report!acute!symptoms,!bacteriuria!was!associated!with!pyuria!and!increased!urinary!
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CXCLM8!production!without!any!elevation!in!urinary!ILM6.!In!another!small!inoculation!
study,!eight!women!with!a!history!of!recurrent!UTI!were!inoculated!with!UPEC!(467).!
No!association!between!the!entry!of!leucocytes!into!the!lower!urinary!tract!and!ILM6!
secretion!was!identified.!Whether!these!patients!developed!symptoms!after!
inoculation!is!unclear.!!
!
Data!from!a!prospective!study!of!recurrent!UTI!in!women!suggests!that!the!initial!ILM
6!response!in!patients!who!develop!acute!symptomatic!UTI!is!pronounced!(258).!
How!this!ILM6!response!changes!as!symptomatic!infection!evolves!or!resolves!
remains!unclear.!The!ILM6!response!after!the!onset!of!symptoms!was!not!reported!in!
this!work.!The!nature!of!the!inflammatory!response!associated!with!bacterial!
infection!could!differ!amongst!patient!groups!with!different!symptomatic!
presentations.!!
!
Hedges!(1991)!did!report!the!mucosal!secretion!of!ILM6!following!inoculation,!
although!it!is!unclear!whether!these!patients!were!symptomatic!(467).!InterleukinM6!
was!secreted!in!an!intermittent!fashion!over!the!first!48!hours!after!inoculation,!
despite!sustained!colonisation.!Further!data!from!prospective!studies!of!UTI!are!
needed!to!corroborate!these!findings.!InterleukinM6!production!is!subject!to!a!
complex!regulatory!system!governed!by!membraneMbound!and!soluble!receptors,!
and!modulated!by!a!host!of!other!influences!(468).!The!intermittent!secretion!of!ILM6!
following!inoculation!may!reflect!these!regulatory!systems!moderating!ILM6!
production.!It!is!known!that!some!strains!of!UPEC!have!developed!strategies!to!
circumvent!the!immune!response!by!suppressing!cytokine!responses!to!infection!
(469M471).!Whether!bacterial!factors!could!influence!the!nature!of!ILM6!secretion!
described!above!is!not!known.!Whilst!the!onset!of!acute!bacterial!cystitis!appears!to!
be!associated!with!an!increase!in!urinary!ILM6!secretion!(258),!the!nature!of!any!
continuing!cytokine!response!requires!further!study.!Whether!ILM6!will!prove!to!be!a!
useful!marker!of!disease!activity!in!UTI!is!unclear.!!!
!
The!statistical!plan!for!this!study!specified!a!multilevel!analysis!to!explore!the!
relationship!between!bacterial!growth,!urinary!symptoms!and!lower!urinary!tract!
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function.!When!the!analysis!was!conducted,!model!assumptions!were!violated!
precluding!meaningful!interpretation!of!the!results.!Whilst!the!magnitude!of!
parameter!estimates!in!mixed!model!analysis!are!unaffected!by!deviations!from!
normality,!the!variance!of!these!estimates!are!often!rendered!inaccurate!(472).!This!
makes!interpretation!of!statistical!significance!unreliable.!!
!
The!relationship!between!these!variables!was!subsequently!approached!from!
another!perspective.!Symptoms!and!lower!urinary!tract!function!data!were!entered!
as!dependent!variables!in!individual!models.!Markers!of!infection!and!inflammation!
were!selected!as!fixed!effects.!This!approach!allowed!the!analyses!to!control!for!the!
effects!of!pharmacological!agents!used!to!attenuate!LUTS.!From!a!design!
perspective,!this!was!a!deviation!from!the!planned!analysis,!but!the!alternative!
would!have!been!to!abandon!any!assessment!of!the!relationship!between!infection!
and!the!generation!of!symptoms.!In!order!to!minimise!the!number!of!models!used!to!
scrutinise!this!relationship,!the!dependent!variables!were!confined!to!urinary!
urgency,!which!defines!the!OAB!syndrome,!and!bladder!diary!data.!!
!
Accounting!for!variable!multiplicity!in!each!of!the!models,!only!pyuria!demonstrated!
a!relationship!with!symptoms!and!function.!Pyuria!predicted!urgency!scores,!24Mhour!
urinary!frequency!and!voided!volume,!although!there!was!no!association!with!
incontinence!episodes.!These!findings!were!independent!of!routine!culture!status.!
Whilst!pyuria!repeatedly!demonstrated!a!relationship!to!urgency!and!bladder!
function,!none!of!the!other!measures!of!infection,!inflammation,!or!urothelial!
distress!were!associated!with!these!outcomes.!The!consensus!amongst!the!results!
provides!reassurance!that!the!use!of!more!than!one!model!to!describe!these!
relationships!did!not!yield!a!type!1!error.!
!
The!use!of!anticholinergic!drugs,!DDAVP,!and!TCA!agents!was!not!associated!with!
significant!changes!in!urgency!or!bladder!function!data.!Whilst!anticholinergic!
medications!are!often!advocated!to!treat!OAB!symptoms!in!MS,!such!
recommendations!are!extrapolated!from!the!study!of!patients!with!OAB!symptoms!
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without!neurological!disease!(157).!Whilst!widely!used,!there!remains!insufficient!
data!to!support!the!efficacy!of!these!drugs!in!patients!with!MS!(158).!!
!
The!minimal!clinically!important!difference!(MCID)!is!a!term!used!to!define!the!
minimum!change!in!a!symptom!measure!that!a!patient!would!identify!as!clinically!
important.!In!validation!studies!conducted!in!patients!with!idiopathic!OAB,!a!
reduction!in!urgency!score!of!two!points!was!associated!with!the!patient!reporting!
that!they!were!‘better’!rather!than!‘no!better’!or!‘worse’!(473).!The!MCID!is!subject!
to!spectrum!bias!and!whether!a!comparable!a!value!is!applicable!to!MS!patients!with!
OAB!symptoms!is!unclear.!There!are!no!intervention!studies!that!have!employed!the!
urgency!score!solely!in!MS!patient!samples.!Nonetheless,!a!reduction!in!pyuria!of!a!
magnitude!that!would!mediate!a!clinically!meaningful!change!in!urgency!ought!to!be!
achievable!based!on!clinical!experience!treating!urinary!infection!associated!with!
pyuria.!
!
Log!pyuria!predicted!24Mhour!urinary!frequency,!although!in!common!with!urinary!
urgency,!any!clinical!effect!would!be!expected!to!correlate!with!the!fall!in!pyuria!
afforded!by!treatment.!Nonetheless,!even!a!small!decline!in!pyuria!would!be!
expected!to!mediate!a!reduction!in!urinary!frequency!greater!than!that!associated!
with!anticholinergic!medication.!When!used!to!treat!idiopathic!OAB!symptoms,!
anticholinergic!drugs!confer!a!mean!reduction!in!urinary!frequency!of!around!0.5!
voids/24!hours!when!compared!to!placebo!(157).!
!
An!increase!in!voided!volume!associated!with!falling!pyuria!was!also!demonstrated.!
A!reduction!in!pyuria!of!1!log!wbc!μlM1!would!be!expected!to!be!associated!with!an!
increase!in!voided!volume!of!39ml!(95%!CI=18M60ml).!This!is!comparable!to!the!
effect!of!treatment!with!the!classMleading!anticholinergic!drug!in!patients!with!nonM
neurogenic!OAB!symptoms!(474).!An!effect!size!of!this!magnitude!could!conceivably!
be!achieved!employing!antibiotic!therapy!in!patients!with!bacterial!infection!and!
associated!urothelial!inflammation.!!
!
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Pyuria!did!not!demonstrate!any!significant!association!with!incontinence!episodes.!
Existing!data!have!demonstrated!that!samples!with!average!daily!incontinence!
episodes!of!less!than!one!are!likely!to!be!insensitive!to!treatment!effects!or!the!
influence!of!other!variables!(475).!At!baseline,!median!daily!incontinence!amongst!
patients!in!this!study!was!zero!(IQR=0.0M0.5).!Based!on!these!data,!the!analysis!
presented!here!was!underpowered!to!demonstrate!an!association!between!
incontinence!and!pyuria,!if!one!exists.!
!
Atypical!and!anaerobic!organisms!were!not!targeted!by!the!culture!methods!used!in!
this!study!and!the!impact!of!this!strategy!on!the!study!findings!is!unclear.!From!an!
analytical!perspective,!the!cultivation!of!additional!bacteria!afforded!by!more!
complex!culture!media!would!be!expected!to!strengthen!the!relationship!between!
infection!and!inflammation,!rather!than!weaken!the!associations!reported!here.!
Some!patient!samples!in!this!work!demonstrated!pyuria!but!no!bacterial!growth.!
Whether!the!use!of!media!and!culture!conditions!to!capture!fastidious!and!
anaerobic!microbes!would!have!implicated!bacterial!infection!in!the!generation!of!
urothelial!inflammation!in!these!samples!is!not!known.!
!
Enrolled!patients!were!invited!to!receive!their!clinical!care!at!the!study!centre,!
subject!to!the!agreement!of!their!general!practitioner.!The!outpatient!service!has!
particular!expertise!in!the!management!of!the!MS!bladder.!Where!evidence!of!
urinary!infection!was!identified!in!association!with!LUTS,!treatment!with!an!
extended!course!of!urinary!antibiotic!was!initiated!at!full!dose!for!up!to!six!months.!
This!approach!contrasts!with!the!provision!of!short!courses!of!antibiotic!offered!in!
most!clinical!services,!or!lowMdose!prophylaxis!recommended!for!recurrent!
infections.!The!nature!and!duration!of!antibiotic!treatment!was!moderated!by!
clinical!assessment!that!included!a!systematic!symptom!review!and!urinalysis!for!
pyuria.!This!approach!evolved!through!clinical!observation!and!data!from!one!
prospective!study!(273).!!!
!
It!is!unlikely!that!the!method!of!antibiotic!treatment!administered!to!patients!
influenced!the!study!findings.!Protracted!courses!of!antibiotic!might!attenuate!
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bacterial!growth!for!long!periods,!mediating!a!sustained!reduction!in!urothelial!
inflammation,!but!there!would!be!no!expectation!that!the!nature!of!treatment!could!
manipulate!the!interaction!between!these!variables.!It!is!the!antimicrobial!property!
of!antibiotics!that!is!assumed!to!reduce!the!bacterial!load!in!the!lower!urinary!tract!
thereby!restraining!tissue!damage!and!inflammation.!
!
Some!antibiotics!do!exhibit!antiMinflammatory!effects.!Macrolides,!quinolones!and!
tertacycline!antibiotics!have!been!shown!to!suppress!some!immune!responses!in!
animal!studies!and!human!cell!line!experiments,!although!in!vivo!data!are!limited.!
The!available!data!have!been!extensively!reviewed!by!Labro!(2000)!and!Tauber!
(2008)!(476,!477).!Only!macrolide!antibiotics!have!been!shown!to!mediate!beneficial!
immunomodulatory!effects!in!clinical!studies.!!SeventyMone!percent!of!the!antibiotics!
used!by!patients!during!this!study!were!nitrofurantoin!or!betaMlactam!antibiotics!
such!as!cefalexin.!There!is!no!evidence!that!these!agents!are!able!to!mediate!
immunosuppression!(476,!477).!Some!patients!used!ciprofloxacin,!which!is!a!
quinolone,!and!doxycycline,!a!tetracycline!antibiotic,!but!clinical!studies!have!not!yet!
demonstrated!that!these!agents!have!a!detectable!immunosuppressive!effect.!Based!
on!these!data,!the!bactericidal!activity!of!antibiotics!is!likely!to!eclipse!any!
theoretical!immunomodulatory!effects!on!urothelial!inflammation.!
!
Although!variations!in!the!provision!of!antibiotic!therapy!treatment!would!not!be!
expected!to!influence!the!relationships!described!in!this!work,!the!nature!of!
treatment!might!affect!symptom!palliation.!If!the!link!between!bacterial!infection!
and!the!generation!of!symptoms!is!causal,!clinical!studies!are!needed!to!determine!
how!this!problem!is!best!approached.!This!was!not!an!intervention!study!and!whilst!
the!data!generated!provide!evidence!of!a!link!between!infection,!urothelial!
inflammation!and!symptom!generation,!they!do!not!inform!on!how!these!patients!
are!best!managed.!!
!
Whilst!the!use!of!an!extended!antibiotic!treatment!period!appears!capable!of!
attenuating!infection!and!symptom!generation!in!this!group!of!patients,!the!
superiority!of!this!approach!to!standard!treatment!remains!unproven.!Whilst!singleM
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dose!and!threeMday!courses!of!antibiotic!are!often!recommended!for!acute!cystitis,!
longer!courses!of!treatment!are!associated!with!lower!bacteriological!recurrence!
rates.!Two!metaManalyses,!including!48!RCTs,!have!demonstrated!that!bacteriological!
recurrence!within!eight!weeks!of!treatment!for!bacterial!cystitis!is!significantly!lower!
when!antibiotics!are!administered!for!two!weeks!(478,!479).!Future!studies!that!
explore!the!antibiotic!treatment!of!patients!with!chronic!urinary!symptoms!should!
specifically!examine!the!efficacy!of!standard!and!extended!treatment!protocols.!!
Recent!data!have!demonstrated!the!capability!of!uropathogenic!bacteria!to!establish!
an!intracellular!niche!in!the!lower!urinary!tract!that!may!confer!protection!from!
immune!and!antibiotic!attack!(224M226).!It!is!tempting!to!implicate!such!intracellular!
infection!in!the!generation!of!chronic!LUTS!but!this!is!no!more!than!speculation!at!
present.!The!inherent!resistance!of!these!organisms!to!antimicrobials!would!support!
clinical!observations!that!only!prolonged!courses!of!treatment!supported!persistent!
symptom!palliation!but!this!requires!further!study.!Intracellular!bacterial!
colonisation!has!been!demonstrated!in!patients!with!chronic!symptoms!(270,!404)!
but!the!prevalence!of!intracellular!infection!amongst!patients!with!LUTS!and!their!
role!in!symptom!generation!is!not!known.!
!
Whilst!these!data!demonstrate!an!association!between!bacterial!infection,!urothelial!
inflammation!and!the!overactive!bladder,!a!precise!description!of!how!these!
symptoms!might!be!generated!remains!unclear.!In!the!neurogenic!bladder,!the!loss!
of!higher!neural!control!mechanisms!and!the!emergence!of!automatic!voiding!
reflexes!were!traditionally!thought!to!mediate!the!symptoms!of!OAB.!This!view!has!
been!challenged!by!data!demonstrating!functional!changes!to!afferent!as!well!as!
efferent!signalling,!and!even!urothelial!barrier!dysfunction!associated!with!CNS!
damage!(89,!105,!121,!122).!!
!
In!patients!without!neurological!disease,!uncontrolled!detrusor!contractions!are!
widely!perceived!to!generate!the!symptoms!of!OAB.!The!cause!of!this!unregulated!
activity!has!not!been!elucidated!but!hypotheses!including!spontaneous!‘myogenic’!
activity!arising!within!the!detrusor!itself!(480)!and!reduced!CNS!inhibition!of!the!
sacral!parasympathetic!nuclei!(481)!have!been!offered.!Urodynamic!studies!are!
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widely!employed!in!patients!with!OAB!symptoms!to!detect!these!unsolicited!
detrusor!contractions!and!corroborate!the!history!with!an!objective!‘urodynamic’!
diagnosis.!However,!in!a!study!of!843!women!with!OAB!symptoms,!only!46%!of!
patients!demonstrated!detrusor!contractions!during!testing!(482).!In!another!
urodynamic!study,!only!half!of!patients!who!demonstrated!detrusor!contractions!
experienced!a!sensation!of!associated!urinary!urgency!when!these!contractions!
ccurred!(483).!These!data!challenge!the!notion!that!detrusor!overactivity!generates!
the!symptoms!of!OAB!in!patients!without!neurological!damage.!!
!
Anticholinergic!drugs!have!been!the!mainstay!of!treatment!for!OAB!symptoms!(157)!
although!the!recent!development!of!an!adrenoceptor!agonist!has!offered!an!
alternative!(484).!These!drugs!are!thought!to!mediate!their!therapeutic!effects!by!
suppressing!detrusor!contractions.!However,!in!the!doses!used!in!human!studies!
there!is!no!evidence!that!they!block!the!neuromuscular!junction!or!have!a!direct!
effect!on!muscle!relaxation!(485,!486).!The!available!urodynamic!data!from!clinical!
studies!of!anticholinergic!agents!suggest!that!their!therapeutic!effects!are!mediated!
by!a!reduction!in!afferent!outflow!from!the!lower!urinary!tract!rather!than!direct!
inhibition!of!the!detrusor!(485).!Moreover,!the!presence!or!absence!of!detrusor!
overactivity!on!urodynamic!testing!has!not!been!shown!to!determine!treatment!
success!in!patients!with!OAB!(487).!Whilst!these!data!relate!to!patients!with!nonM
neurogenic!OAB!symptoms,!they!are!of!relevance!to!the!findings!of!this!study.!They!
convincingly!challenge!the!belief!that!the!syndrome!is!a!disease!of!the!motor!system,!
driven!by!damage!to!neural!circuits!in!the!case!of!neurological!disease,!or!the!
emergence!of!autonomous!detrusor!activity!in!patients!without!a!neurological!
disorder.!Afferent!signalling!in!the!lower!urinary!tract!appears!to!play!a!significant!
role!in!the!generation!of!OAB!symptoms.!!
!
The!activation!of!TLR4!by!bacterial!LPS!is!known!to!initiate!the!production!of!
cytokines!via!the!NFMκB!signalling!pathway!(216M218).!TollMlike!receptor!activation!
has!recently!been!shown!to!stimulate!the!transcription!of!inflammatory!cytokines!
independent!of!NFMκB!by!mediating!rapid!increases!in!intracellular!Ca2+and!cyclic!
adenosine!monophosphate!(cAMP)!(488).!The!binding!of!the!bacterial!pilus!
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component!FimH!to!UPIII!on!urothelial!cells!is!also!known!to!induce!elevations!in!
cytosolic!Ca2+!(223,!389).!Increases!in!intracellular!calcium!are!a!common!
consequence!of!receptor!activation!in!mammalian!cells!(489)!and!the!release!of!
urothelial!ATP!is!associated!with!elevated!cytoplasmic!Ca2+!(490,!491).!Whether!Ca2+!
signalling!is!implicated!in!the!generation!of!OAB!symptoms!is!unknown.!!
!
Adenosine!triphosphate!is!released!in!response!to!stretch,!cell!damage!and!bacterial!
LPS!(262,!319M322).!Augmented!purinergic!neurotransmission!has!also!been!
demonstrated!in!bladder!tissue!isolated!from!patients!with!lower!urinary!tract!
disorders!including!OAB!(67M75,!92,!93).!Whilst!ATP!has!been!shown!to!activate!
bladder!afferents!and!influence!sensory!outflow!from!the!lower!urinary!tract!(95),!
evidence!for!a!paracrine!effect!in!the!human!bladder!was!unproven!until!recently.!It!
has!now!been!demonstrated!that!urothelialMderived!ATP!is!able!to!influence!the!
detrusor!smooth!muscle!behaviour!through!a!paracrine!mechanism,!and!influence!
the!function!of!other!mucosal!components!(492).!Thus,!purinergic!signalling!in!the!
lower!urinary!tract!might!moderate!sensory!outflow!and!detrusor!function.!The!
urothelium,!lamina!propria!and!detrusor!are!in!close!proximity,!and!there!is!evidence!
of!cellMtoMcell!coupling!mediated!by!gap!junctions!(493).!These!structural!features!
might!facilitate!direct!communication!between!the!mucosa!and!the!detrusor.!
Whether!the!paracrine!action!of!ATP!influences!the!response!of!detrusor!smooth!
muscle!to!neurological!inputs!or!is!capable!of!generating!spontaneous!contractile!
activity!that!might!manifest!as!OAB!symptoms!is!not!known.!
!
The!available!evidence!illustrates!that!lower!urinary!tract!function!is!governed!by!a!
complex!interplay!of!local!and!central!influences.!Whilst!the!neuropathology!of!MS!
disrupts!the!coordinated!control!of!lower!urinary!tract!function,!a!growing!body!of!
evidence!suggests!that!other!influences!may!shape!the!evolution!of!symptoms.!This!
study!suggests!that!urothelial!inflammation!might!contribute!to!the!generation!of!
OAB!symptoms,!although!the!mechanism!by!which!this!might!occur!remains!to!be!
elucidated.!
!
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The!interaction!between!the!neurogenic!component!of!lower!urinary!tract!
dysfunction!and!any!effects!mediated!by!infection!and!inflammation!may!vary!
between!patients.!It!is!conceivable!that!some!patients!have!a!pronounced!infective,!
inflammatory!component!to!their!symptomatology!that!is!potentially!treatable.!In!
others,!the!symptoms!may!be!generated!primarily!as!a!result!of!neurological!
damage.!In!these!patients,!infection!and!urothelial!inflammation!might!be!palliated!
with!antibiotic!treatment!without!symptomatic!benefit!due!to!fixed!neurological!
deficits!affecting!lower!urinary!tract!function.!Nonetheless,!the!data!presented!in!
this!study!suggest!that!those!patients!who!demonstrate!pyuria!might!benefit!from!
treatment.!!
! $
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7 A$randomised,$doubleYblind,$placebo$
controlled,$crossover$trial$of$AIMSPRO$for$
the$treatment$of$overactive$bladder$
symptoms$in$patients$with$secondary$
progressive$multiple$sclerosis$$ $
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7.1 Background$
!
Whilst!a!minority!of!patients!with!MS!will!demonstrate!progressive!disease!at!
diagnosis,!most!will!present!with!the!relapsingMremitting!form!of!the!condition.!
Unfortunately,!at!least!half!of!patients!with!relapsingMremitting!MS!(RRMMS)!will!have!
entered!a!secondary!progressive!phase!at!10M15!years!(51M53).!The!onset!of!
secondary!progressive!MS!(SPMMS)!is!associated!with!a!continuous!and!irreversible!
decline!in!neurological!function.!Progressive!disease,!primary!or!secondary,!is!
associated!with!the!vast!majority!of!disability!for!patients.!
!
Since!the!first!clinical!trial!of!interferon!(IFN)!β−1b!in!RRMS!was!published!over!20!
years!ago,!there!has!been!continued!progress!in!the!treatment!of!this!disease!variant!
(494).!Disease!modifying!agents!that!reduce!the!relapse!rate!have!been!shown!to!
attenuate!the!accumulation!of!disability!(495).!There!is!also!recognition!that!early!
introduction!of!these!drugs!in!patients!with!a!single!demyelinating!episode!may!
delay!the!onset!of!clinically!definite!MS!(496).!
!
In!contrast!to!relapsingMremitting!disease,!there!is!no!conclusive!evidence!that!any!
treatment!halts!neurological!progression!associated!with!SPMMS.!The!European!Trial!
in!SPMMS!(EUSPMS)!tested!IFNβ−1b!against!placebo!but!despite!an!apparent!
reduction!in!disease!progression!in!the!IFN!arm!these!results!were!not!corroborated!
by!another!large!North!American!study!(497).!Further!analysis!has!suggested!that!the!
initial!positive!findings!were!likely!a!result!of!differences!in!the!study!populations.!
The!European!study!enrolled!younger!patients!with!higher!rates!of!relapse!and!a!
greater!prevalence!of!enhancing!lesions!on!MRI!(498).!These!data!suggest!that!the!
impact!of!treatment!on!disability!was!mediated!through!relapse!suppression!rather!
than!a!direct!influence!on!progression.!Based!on!these!data!and!others!(499),!the!use!
of!IFN!in!SPMMS!is!usually!confined!to!patients!with!persistent!relapses.!!
!
Mitoxantrone!is!an!antineoplastic!agent!that!mediates!a!reduction!in!BM!and!TM
lymphocyte!numbers!through!interference!with!DNA!replication!and!repair!(500).!
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The!efficacy!of!mitoxantrone!has!been!examined!in!studies!with!mixed!populations!
of!RRMMS!and!SPMMS!(501,!502).!Whilst!progression!of!existing!disability!was!
retarded!in!the!active!treatment!groups,!these!effects!were!likely!mediated!through!
relapse!suppression!rather!than!a!direct!effect!on!the!underlying!disease!course.!No!
firm!conclusions!can!be!made!relating!to!the!efficacy!of!this!agent!in!patients!with!
SPMMS!who!do!not!experience!ongoing!relapses.!LongMterm!use!of!the!drug!can!be!
associated!with!cardiac!failure!in!around!10%!of!users!and!therapyMrelated!acute!
leukaemia!in!around!0.5%!(503).!!
!
RelapsingMremitting!MS!appears!to!demonstrate!differences!in!its!pathophysiology!
when!compared!to!progressive!disease!variants.!RelapsingMremitting!MS!is!
characterised!acute!episodes!of!demyelination,!mediated!by!T!lymphocytes,!and!as!a!
result!of!macrophage!activity.!By!contrast,!patients!with!progressive!MS!
demonstrate!diffuse!neuroaxonal!loss!(30)!and!new!focal!demyelination!is!much!less!
common!(34,!35).!Axonal!loss!may!occur!as!a!consequence!of!continuous,!grumbling!
inflammation!within!the!CNS,!with!nitric!oxide!and!glutamate!implicated!in!this!
process!(37M39).!The!eventual!failure!of!damaged!but!fragile!axons!may!also!
contribute!to!permanent!loss!of!function!(40).!The!lack!of!efficacy!demonstrated!by!
immunomodulatory!agents!in!progressive!disease!may!be!explained!by!these!
insights.!!
!
Major!histocompatibility!complex!Class!II!proteins!are!key!antigen!presenting!
molecules!in!humans.!Interferon!β,!which!has!a!complex!effect!on!immunological!
function,!is!thought!to!exert!some!of!its!therapeutic!effect!in!MS!through!
suppression!of!MHC!Class!II!activity!(504,!505).!Other!drugs!used!in!relapsing!
remitting!disease!also!disrupt!TMlymphocyte!recognition!of!selfMpeptide.!Glatiramer!
acetate!achieves!this!by!binding!directly!to!MHC!Class!II!proteins!(506)!whilst!
mitoxantrone!suppresses!lymphocyte!numbers!thus!reducing!the!magnitude!of!the!
adaptive!immune!response!(500).!!
!
In!1999,!Capralogics!Incorporated,!a!research!facility!in!Massachusetts,!USA,!was!
contracted!to!assist!in!the!development!of!a!polyclonal!neutralising!antibody!against!
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HIV.!Goats!were!initially!inoculated!with!HIV!antigens!and!the!sera!analysed!to!
determine!whether!HIV!antibodies!could!be!generated!at!high!levels.!The!product!
was!subsequently!found!to!contain!extremely!low!antibody!titres!to!HIV!but!high!
titres!to!MHC!Class!II!proteins.!The!resulting!medication!was!less!effective!than!
conventional!therapy!for!HIV!but!its!potential!antiMinflammatory!effects!made!it!a!
candidate!drug!for!chronic!autoimmune!and!inflammatory!conditions.!Daval!
International,!a!UKMbased!biotechnology!company,!purchased!the!technology!and!
continued!to!develop!the!product!as!AIMSPRO®!(an!acronym!for!AntiMinflammatory!
IMmunoSuppressive!PROduct).!
!
Subsequent!analysis!by!Daval!demonstrated!that!AIMSPRO®!contains!a!complex!of!
molecules!that!may!have!immunomodulatory!effects!(507).!The!product!contains!
hypothalamoMpituitaryMadrenal!(HPA)!regulatory!molecules!including!corticotrophinM
releasing!hormone!(CRH),!arginine!vasopressin!and!βMendorphin.!AIMSPRO®!also!
contains!ProMopiomelanocortin!(POMC),!the!peptide!precursor!of!a!number!of!
pituitary!hormones,!and!the!cytokines!ILM1β and!ILM10.!Daval!claim!that!AIMSPRO®!
can!modify!HPA!axis!function,!resulting!in!the!endogenous!production!and!regulation!
of!melanocortins!including!ACTH,!CRH,!βMendorphin!and!vasopressin.!!
!
Daval!have!reported!that!patients!administered!AIMSPRO®!demonstrate!a!shift!in!
their!cytokine!profile!favouring!antiMinflammatory!effects!(508).!They!propose!that!
these!changes!are!mediated!by!modulation!of!the!HPA!axis!leading!to!enhanced!
glucocorticoid!secretion!and!the!suppression!of!innate!and!adaptive!immune!
responses.!The!influence!of!the!HPA!axis!on!inflammation!is!well!recognised!(509).!
The!action!of!antiMinflammatory!cytokines,!elevated!production!of!melanocyte!
stimulating!hormone!(MSH),!and!direct!effects!on!immune!cell!function!have!been!
proposed!as!mechanisms!by!which!AIMSPRO®!might!mediate!any!antiMinflammatory!
effects!(507).!
!
Neurophysiological!data!from!threshold!tracking!experiments!have!suggested!that!
AIMSPRO®!might!be!able!to!improve!conduction!in!damaged!nerves.!In!one!patient!
with!Chronic!Demyelinating!Inflammatory!Polyradiculoneuropathy,!enhanced!nerve!
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excitability!was!reported!after!treatment.!This!was!implied!by!a!reduction!in!the!
triggering!voltages!of!sodium!channels!in!peripheral!nerves!and!a!prolongation!of!
channel!opening!after!AIMSPRO®!administration!(510).!This!observation!has!been!
corroborated!in!one!other!report!(511).!
!
Over!the!last!decade,!Daval!has!promoted!AIMSPRO®!as!a!putative!treatment!for!a!
variety!of!human!diseases!without!direct!evidence!of!efficacy.!Although!unlicenced,!
it!is!registered!as!a!‘special’!with!the!MHRA,!allowing!its!provision!on!a!named!
patient!basis!when!clinical!need!cannot!be!met!by!a!licenced!product.!Responsibility!
for!the!use!of!these!drugs!lies!solely!with!the!prescribing!physician!and!any!adverse!
drug!reactions!must!be!reported!(512).!Outside!the!UK,!similar!schemes!that!permit!
the!use!of!unlicenced!medications!in!this!manner!are!known!as!‘compassionate!use’!
or!‘expanded!access’!programmes!(513).!!
!
Data!relating!to!the!therapeutic!use!of!AIMSPRO®!are!limited!to!clinical!observations!
and!case!reports!(275,!514M520).!Whilst!only!two!published!reports!describe!the!use!
of!AIMSPRO®!in!MS!(517,!519),!over!400!patients!with!the!condition!have!now!taken!
AIMSPRO®!on!compassionate!grounds!for!periods!of!up!to!five!years.!Objective!
improvement!has!been!claimed!in!some!cases,!but!these!observations!are!
uncontrolled,!and!documented!in!personal!communications!between!prescribing!
clinicians!and!Daval!(514).!Daval!also!claim!improvements!in!fatigue!and!bladder!
control,!colour!vision,!balance!and!mobility!that!they!suggest!may!manifest!rapidly!
after!administration!(514).!Daval!has!proposed!that!these!perceived!improvements!
are!a!consequence!of:!(1)!the!general!antiMinflammatory!effects!of!the!agent!(507,!
508);!and!(2)!the!enhancement!of!sodium!channel!activation!in!damaged!nerves!
(510,!511).!
!
Since!AIMSPRO®!was!first!granted!authorisation!for!compassionate!use,!Daval!has!
never!been!far!from!controversy.!The!first!randomised!study!of!AIMSPRO®!in!
patients!with!SPMMS!was!halted!after!a!dispute!between!Daval!and!researchers!at!St!
George’s!Hospital,!London,!over!standards!of!preservation!of!the!study!drug.!
Disability!data!were!collected!from!all!47!enrolled!patients!but!the!results!were!not!
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made!public!as!the!dispute!was!never!resolved.!A!second!much!smaller!trial!in!
patients!with!MS!and!a!previous!episode!of!optic!neuritis!was!conducted!at!the!John!
Radcliffe!Hospital,!Oxford.!No!evidence!of!benefit!was!demonstrated!in!the!primary!
or!secondary!outcome!measures!(521).!Allegations!of!improper!conduct!relating!to!
the!marketing!and!provision!of!AIMSPRO®!were!reported!in!the!UK!press,!and!Daval!
was!accused!of!misrepresenting!study!data!for!commercial!gain!(522,!523).!These!
claims!were!investigated!by!the!MHRA,!but!after!a!lengthy!consultation,!no!charges!
were!brought!against!Daval.!!!
!
A!recent!review!of!compassionate!use!drug!programmes!in!ten!EU!countries!has!
highlighted!the!potential!problems!with!such!schemes!(513).!Whilst!these!
programmes!were!conceived!to!try!and!help!patients!for!whom!licenced!medications!
offer!no!hope!of!palliation,!those!seeking!such!treatments!represent!a!vulnerable!
group.!Such!individuals!may!be!more!likely!to!pursue!expensive!drug!therapies!
despite!a!lack!of!data!relating!to!efficacy!and!safety.!In!contrast!to!clinical!trials,!
these!programmes!do!not!offer!safeguards!to!patients!including!ethical!review,!
informed!consent!and!insurance!for!adverse!events.!!
!
Compassionate!use!programmes!must!not!offer!an!easy!method!of!collecting!
efficacy!and!safety!data!on!a!new!product.!They!are!not!a!substitute!for!clinical!trials,!
necessary!to!satisfy!regulatory!authorities!and!bring!effective!therapies!to!a!wider!
population!of!patients.!Randomised!studies!also!offer!guaranteed!access!to!a!study!
drug!for!patients!who!benefitted!once!a!trial!has!ended.!Furthermore,!if!the!drug!is!
found!to!be!safe!and!effective,!positive!results!catalyse!expanded!access!to!the!
treatment!whilst!licencing!is!being!sought.!Whilst!compassionate!use!programmes!
were!conceived!to!help!those!whose!suffering!cannot!be!palliated!by!conventional!
means,!patients!must!be!protected.!
!
During!openMlabel!observations!in!patients!with!MS,!one!of!the!most!consistent!
benefits!of!AIMSPRO®!administration!was!a!reported!improvement!in!lower!urinary!
tract!function!that!appeared!rapid!in!onset.!In!view!of!these!reports,!Daval!
approached!Professor!James!MaloneMLee!to!evaluate!the!efficacy!and!safety!of!
! ! 240!
AIMSPRO®!in!the!treatment!of!OAB!symptoms!in!patients!with!MS.!After!some!
hesitation,!Professor!MaloneMLee!met!with!Daval!regarding!the!proposal.!He!agreed!
to!take!on!the!trial!because!he!believed!that!he!could!offer!a!rapid!and!effective!
means!of!resolving!the!controversy!surrounding!AIMSPRO®.!His!agreement!was!
subject!to!the!study!meeting!all!MHRA!regulatory!requirements!and!the!production!
of!AIMSPRO®!to!Good!Manufacturing!Practice!(GMP)!standards.!Whilst!efficacy!was!
unproven,!AIMSPRO®!appeared!to!be!safe.!Records!from!Daval!documented!the!
provision!of!more!than!19,000!individual!vials!of!product!to!patients,!apparently!
administered!without!any!notable!adverse!effects!(524).!No!significant!adverse!
reactions!were!reported!in!either!of!the!randomised!studies!that!were!undertaken!in!
Oxford!or!London!(525).!
!
Large,!parallelMgroup!randomised!studies!are!often!deployed!to!test!new!treatments!
for!LUTS.!A!recent!phase!IIa!randomised!study!that!evaluated!a!new!treatment!for!
OAB!symptoms!enrolled!hundreds!of!patients!in!several!countries!(526).!The!costs!of!
large!RCTs!can!be!prohibitive!for!smaller!biotechnology!companies!looking!to!
develop!new!treatments!(527,!528).!In!2003,!Professor!James!MaloneMLee!and!Alex!
Yaroshinsky,!a!Roche!Bioscience!statistician,!developed!a!randomised,!crossover!trial!
design!that!could!be!used!for!proof!of!concept!studies!using!a!small!sample!size!of!20!
patients!(475).!The!sample!size!calculation!is!powered!to!detect!a!mean!increase!in!
voided!volume!of!60ml,!which!has!been!associated!with!clinically!significant!
improvements!in!lower!urinary!tract!function!reported!by!patients!(529).!!This!design!
contrasts!with!large!parallelMgroup!studies!that!are!often!powered!to!detect!smaller!
effect!sizes!that!might!be!statistically!significant!but!of!questionable!clinical!value.!
!
The!design!permits!the!rapid!assessment!of!new!treatments!that!is!costMeffective.!
Failure!to!detect!an!effect!using!this!approach!implies!that!the!drug!would!be!
unlikely!to!demonstrate!a!clinically!useful!response.!This!would!allow!its!
development!to!be!halted!at!an!early!stage,!minimising!investment!in!a!treatment!
unlikely!to!make!it!to!market.!This!method!has!been!used!successfully!in!the!
evaluation!of!new!treatments!for!OAB,!mitigating!the!need!for!larger!studies!in!early!
drug!development!programmes!(530M532).!
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The!crossover!study!has!two!short!treatment!phases,!separated!by!a!‘washout!
period’!during!which!the!participant!remains!free!of!investigational!drug.!The!use!of!
a!crossover!design!is!contingent!on!the!absence!of!any!measurable!‘crossover!
effect’.!Thus,!the!investigational!drug!must!have!the!potential!to!moderate!clinical!
manifestations!of!the!disease!rapidly,!but!these!effects!must!be!reversible!on!its!
withdrawal.!The!agent!must!ameliorate!diseaseMrelated!symptoms!only,!not!effect!a!
permanent!cure,!and!must!be!rapidly!eliminated!after!therapy!is!discontinued.!This!is!
dependent!on!pharmacokinetic!characteristics!and!the!proposed!duration!of!the!
washout!period.!Based!on!the!presumed!pharmacology!of!AIMSPRO®!and!clinical!
observations,!a!randomised!crossover!design!was!deemed!a!suitable!means!of!
evaluating!the!effects!of!the!drug!on!lower!urinary!tract!function.!
!
Not!unexpectedly,!there!was!significant!resistance!to!the!study.!Concerns!about!the!
alleged!conduct!of!Daval!and!a!litigious!approach!to!critics!stalled!the!development!
of!the!trial!for!almost!five!years.!Despite!ethical!approval!being!granted!by!the!NRES,!
the!research!ethics!committee!at!the!NHS!Trust!that!was!approached!to!host!the!
trial!rejected!the!study.!This!prompted!the!Chairman!of!the!NRES!committee!that!
provided!ethical!approval!to!seek!legal!advice!and!appeal!to!the!Health!Research!
Authority.!Although!local!ethical!objections!to!the!study!were!overturned,!the!Chief!
Executive!of!the!NHS!Trust!then!vetoed!the!study.!The!trial!was!finally!accepted!by!
another!Trust!in!London.!!
!
Whilst!attempts!to!prevent!this!study!being!undertaken!were!perhaps!inevitable,!
they!were!not!ultimately!in!the!patient!interest.!Irrespective!of!concerns!about!the!
alleged!conduct!of!Daval,!clinical!trial!data!were!required!to!address!their!assertions!
and!provide!answers!for!patients.!These!aims!cannot!be!achieved!by!an!embargo.!
Previous!clinical!trials!of!AIMSPRO®!had!unfortunately!failed!to!resolve!the!claims!
and!counterMclaims!relating!to!the!efficacy!of!AIMSPRO®.!Proof!of!concept!studies!
conducted!in!this!centre!have!repeatedly!demonstrated!that!such!disputes!can!be!
resolved!quickly!whilst!maintaining!scientific!standards!and!limiting!financial!burden.!
Professor!MaloneMLee!believed!that!the!controversies!relating!to!AIMSPRO®!could!be!
dealt!with!by!these!means.!This!was!a!view!shared!by!The!MS!Society!in!the!UK!(533)!
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although!the!problems!encountered!during!previous!controlled!trials!of!AIMSPRO®!
remained!a!concern.!Whilst!Daval!sponsored!the!study,!Professor!MaloneMLee!
worked!with!complete!autonomy!for!the!duration!of!the!trial.!Liaison!with!Daval’s!
Medical!Director!was!necessary!to!satisfy!regulatory!requirements!but!no!other!
contact!between!investigators!and!Daval!was!sanctioned.!
!
In!addition!to!bladderMrelated!treatment!effects,!Daval!wished!to!collect!data!on!
disease!status,!neurological!function!and!measures!of!the!inflammatory!response.!
They!argued!that!if!the!study!demonstrated!evidence!of!an!effect,!these!analyses!
would!help!to!characterise!the!physiological!mechanisms!mediating!such!an!effect!if!
it!existed.!An!openMlabel!extension!of!the!RCT!was!also!agreed!to!evaluate!the!safety!
of!AIMSPRO®!during!extended!administration.!Measures!of!bladder!and!neurological!
function!were!also!collected!during!the!openMlabel!phase,!in!order!to!identify!any!
effects!associated!with!the!prolonged!administration!of!the!drug.!If!evident,!such!
data!might!justify!longer!controlled!trials!of!AIMSPRO®!in!the!future.!!
!
It!was!made!clear!from!the!outset!that!secondary!outcome!measures!relating!to!
neurological!function,!exploratory!analyses!and!data!from!openMlabel!observations!
would!be!used!to!guide!future!research!only.!Any!positive!findings!amongst!these!
measures!were!not!to!be!reported!by!Daval!as!evidence!of!AIMSPRO®!modifying!the!
neurological!course!of!SPMMS!without!further!study.!The!trial!was!powered!only!to!
detect!a!clinically!significant!effect!on!the!primary!outcome!that!assessed!lower!
urinary!tract!function.!All!other!findings!were!to!be!treated!with!caution.!This!was!
agreed!by!all!parties!and!recorded!explicitly!in!the!study!protocol.!Nonetheless,!the!
collection!of!exploratory!data!was!in!the!wider!interest.!!
!
In!view!of!proposed!physiological!effects!of!AIMSPRO®,!any!improvements!in!lower!
urinary!tract!function!in!MS!might!be!mediated!by!two!complementary!pathways:!(1)!
drug!effects!on!CNS!inflammation!and!nerve!conduction!mediating!an!improvement!
in!neurological!function;!and!(2)!local!immunomodulatory!and!antiMinflammatory!
effects!in!the!bladder.!The!second!of!these!hypotheses!was!apposite!to!this!
programme!of!study.!If!the!administration!of!AIMSPRO®!was!associated!with!an!
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improvement!in!bladder!function,!cytokine!analyses!and!neurological!testing!might!
help!to!elucidate!the!mechanisms!by!which!such!effects!were!mediated.!
!
! $
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7.2 Study$overview$
!
Adult!patients!with!SPMMS!participated!in!a!phase!IIa!randomised,!doubleMblind,!
placebo!controlled!trial!to!determine!the!efficacy!and!safety!of!AIMSPRO®!in!the!
treatment!of!OAB!symptoms.!Participants!had!to!comply!with!the!inclusion!and!
exclusion!criteria!set!out!in!the!protocol!and!demonstrate!no!evidence!of!UTI!using!
methods!common!to!ordinary!clinical!practice.!A!crossover!design!was!employed,!
with!two!treatment!phases!lasting!28!days,!separated!by!a!washout!period!of!42!
days.!During!each!of!the!treatment!phases,!the!investigational!drug!or!placebo!was!
administered!twice!weekly!as!a!subMcutaneous!injection,!under!doubleMblind!
conditions.!
!
All!patients!attended!a!screening!visit!to!assess!eligibility,!including!an!assessment!by!
a!consultant!neurologist!to!verify!the!diagnosis!of!SPMMS!prior!to!inclusion.!Eligible!
patients!were!assessed!at!three!visits!during!each!treatment!phase.!Lower!urinary!
tract!function!was!evaluated!using!bladder!diary!data!and!urinary!symptoms!were!
assessed!by!validated!questionnaires.!Disability!and!neurological!status!were!
evaluated!using!a!combination!of!functional!testing!and!questionnaire!data.!
Threshold!tracking!experiments!were!conducted!to!assess!peripheral!nerve!
excitability!after!administration!of!AIMSPRO®.!An!exploratory!analysis!of!serum!and!
urine!cytokine!expression!was!conducted!to!evaluate!the!effects!of!the!drug!on!the!
inflammatory!response.!Safety!was!evaluated!by!serial!laboratory!analysis!of!
haematological,!biochemical!and!immunological!indices,!clinical!examination!and!
adverse!event!analysis.!
!
An!openMlabel!extension!of!the!study!was!approved!to!assess!the!safety!of!
AIMSPRO®!during!prolonged!administration.!Observational!data!evaluating!lower!
urinary!tract!function,!urinary!symptoms,!general!disability!and!neurological!function!
were!also!collected!during!this!period.!
!
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The!study!was!conducted!at!the!Department!of!Neurophysiology,!Royal!Free!London!
NHS!Foundation!Trust.!!Ethical!approval!was!granted!by!the!NRES!Committee!
London,!Queen’s!Square!(Ref:!10/H0716/84).!
!
7.3 Safety$considerations$
!
The!only!adverse!reactions!reported!in!association!with!AIMSPRO®!administration!
are!cutaneous!reactions!at!the!injection!site.!These!reactions!are!typically!
erythematous,!pruritic!and!are!usually!two!to!three!centimetres!in!maximum!
diameter.!Around!10%!of!users!report!injection!site!reactions!that!are!usually!
alleviated!with!oral!antihistamines!(525).!Clinical!experience!would!suggest!that!
these!reactions!are!rare!once!the!duration!of!therapy!has!exceeded!two!months.!!
!
No!significant!adverse!reactions!were!identified!in!either!of!the!previous!randomised!
trials!of!AIMSPRO®.!!At!the!time!of!writing,!no!adverse!effects!had!been!logged!
through!the!MHRA!“Yellow!Card”!system!in!the!UK,!or!reported!to!Daval!by!
prescribing!physicians!in!Canada,!New!Zealand!and!Australia!(525).!Prior!to!the!
submission!of!the!study!protocol,!14!patients!who!had!been!receiving!AIMSPRO®!for!
between!two!and!five!years!were!examined!by!an!independent!physician.!No!
significant!clinical!or!laboratory!abnormalities!were!identified!in!any!of!the!patients!
(534).!
$
7.4 Study$objectives$
!
7.4.1 Primary$objective$
!
− To!evaluate!whether!the!regular!administration!of!AIMSPRO®!improves!OAB!
symptoms,!demonstrated!by!a!significant!increase!in!average!voided!volume!
derived!from!bladder!diary!data.!
!!
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7.4.2 Secondary$objectives$$
!
The!secondary!objectives!of!the!study!were!to!determine!the!following:!
!
− The!effects!of!AIMSPRO®!administration!on!urinary!frequency!and!incontinence!
episodes!derived!from!bladder!diary!data.!
− The!effects!of!AIMSPRO®!administration!on!symptoms!of!urinary!urgency!and!
bladderMrelated!QoL!using!validated!questionnaires.!
− The!effects!of!AIMSPRO®!administration!on!the!physical!and!psychological!health!
of!patients!using!validated!questionnaires.!
− The!effects!of!AIMSPRO®!administration!on!ambulatory!and!cognitive!
impairment!using!functional!composite!testing.!
− The!effects!of!AIMSPRO®!administration!on!colour!vision!and!visual!acuity!using!
the!FansworthMMunsell!and!LogMAR!tests.!!
!
7.4.3 Tertiary$objectives$
!
The!tertiary/exploratory!objectives!of!the!study!were!to!determine!the!following:!
!
− The!effects!of!AIMSPRO®!administration!on!peripheral!nerve!conduction!
determined!by!threshold!tracking!studies.!
− The!effects!of!AIMSPRO®!administration!on!serum!and!urine!biomarkers.!
!
7.4.4 Safety$objectives$
!
The!safety!of!AIMSPRO®!was!assessed!by!means!of!adverse!event!reporting!
throughout!the!blinded!and!openMlabel!phases!of!the!study.!The!frequency!and!
nature!of!all!adverse!events!were!summarised!and!classified!using!standard!
methods.!
!
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7.5 Study$population$
!
7.5.1 Recruitment$of$participants$
!
Patients!and!control!subjects!were!recruited!as!outlined!previously!(2.2.2).!!
$
7.5.2 Consent$and$eligibility$
!
All!participants!provided!written,!informed!consent!prior!to!any!study!related!
procedures,!and!eligibility!was!checked!before!inclusion!(2.2.3).!!
!
7.5.3 Inclusion$and$exclusion$criteria$
!
Ambulant!adult!patients!with!SPMMS,!urinary!urgency,!and!24Mhour!urinary!frequency!
≥8!were!eligible!for!inclusion.!The!diagnosis!of!SPMMS!was!made!using!the!modified!
McDonald!diagnostic!criteria,!published!in!2005!(535).!The!exclusion!of!UTI!using!
standard!urinalysis!methods!was!essential!prior!to!study!inclusion.!No!more!than!one!
relapse!in!the!last!12!months!was!permitted.!Any!relapse!in!the!six!months!prior!to!
screening!precluded!participation.!A!full!list!of!inclusion!and!exclusion!criteria!are!
described!in!Table$33!and!Table$34.!
!
7.5.4 Study$restrictions$and$concomitant$medications$
!
The!use!of!any!immunosuppressive!therapy!during!the!study!was!prohibited,!
although!a!short!course!of!corticosteroid!therapy,!oral!or!intravenous,!was!permitted!
for!a!disabling!relapse!of!MS!when!recommended!by!a!neurologist.!!
!
The!use!of!all!concomitant!medication!was!recorded!in!the!study!documentation.!
This!included!all!prescription!drugs,!overMtheMcounter!medications,!herbal!remedies,!
vitamins,!minerals!and!supplements.!
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Table!33!Inclusion!criteria.!
!
Inclusion$criteria!
1! Adult!patients!with!MS!
2! Agreement!to!use!adequate!birth!control!measures!for!the!duration!of!the!study!and!for!six!
months!after!receiving!the!last!dose!of!the!study!drug!
3! A!diagnosis!of!clinically!definite!SPMMS!
4! The!ability!to!walk,!with!or!without!walking!aids!
5! No!more!than!one!relapse!within!the!last!12!months!and!no!relapse!within!the!last!6!months!
6! Urinary!urgency!with!or!without!urgency!incontinence!
7! 24Mhour!urinary!frequency!≥8!
8! A!documented!MRI!of!the!brain!or!spinal!cord!demonstrating!features!consistent!with!MS!
9! Screening!laboratory!tests!demonstrating!the!following!parameters:!haemoglobin!≥!9.5!g!dl
M1;!
leucocytes!≥!3.5!x!109!lM1;!neutrophils!≥!1.5!x!109!lM1;!and!platelets!≥!100!x!109!lM1!!
10! Baseline!liver!function,!thyroid!function,!and!serum!electrophoresis!levels!must!be!within!the!
normal!range!for!the!laboratory!conducting!the!test!
11! Ability!to!adhere!to!the!study!visit!schedule!and!other!protocol!requirements!
12! Ability!to!provide!written!informed!consent!prior!to!study!inclusion!
!
!
7.5.5 Discontinuation$of$subject$participation$
!
Patients!could!be!withdrawn!from!the!study!at!the!discretion!of!the!Chief!
Investigator.!The!criteria!for!subject!withdrawal!included:!(1)!nonMcompliance!with!
the!requirements!of!the!protocol;!(2)!an!adverse!event!after!which!continued!
participation!would!present!an!unacceptable!risk;!(3)!withdrawal!on!medical!or!
administrative!grounds;!(4)!if!continued!participation!would!not!be!in!the!patient’s!
best!interests;!(5)!pregnancy.!Patients!could!withdraw!their!consent!to!participate!at!
any!time!without!prejudice!but!would!be!invited!for!followMup!visits!to!monitor!
safety!data.!
!
The!protocol!demanded!that!patients!who!withdrew!in!first!four!weeks!of!the!study!
should!be!replaced.!If!a!patient!withdrew!as!a!result!of!an!adverse!event,!they!would!
remain!under!review!until!the!adverse!event!resolved!or!stabilised.!!
!
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Table!34!Exclusion!criteria.!
!
Exclusion$criteria!
1! Pregnant!or!lactating!women!and!women!!
2! Women!who!are!planning!pregnancy!within!12!months!of!screening!
3! The!use!of!desmopressin!for!nocturia!
4! The!use!of!urinary!catheters!
5! Acute!symptomatic!urinary!infection!
6! Positive!urine!culture!
7! No!clear!progression!of!disability!in!the!last!12!months!
8! Previous!administration!of!AIMSPRO®!
9! The!receipt!of!any!investigational!drug!within!30!days!of!screening!or!within!five!halfMlives!of!
the!drug,!whichever!is!longer!
10! The!receipt!of!any!immunosuppressive!therapy!!
11! The!use!of!the!anticonvulsant!lamotrigine!or!the!antiMarrhythmic!drug!flecainide,!both!of!
which!are!potent!sodium!channel!blocking!agents!
12! A!history!of!severe!allergy!or!any!history!of!allergy!to!animal!proteins!
13! Any!other!neurological!condition!in!addition!to!SPMMS!
14! Established!renal,!hepatic,!haematologic,!gastrointestinal,!endocrine,!pulmonary,!cardiac!
disease!or!malignant!disease!that!would!affect!the!interpretation!of!study!data!
15!
Any!history!of!serious!infections!(such!as!pneumonia!or!pyelonephritis)!within!three!months!
of!screening!(less!serious!infections!such!as!acute!upper!respiratory!tract!infection!or!simple!
urinary!tract!infection,!should!be!followed!to!their!conclusion!or!treated,!as!appropriate,!
prior!to!inclusion)!
16!
Patients!with!opportunistic!infections,!including!but!not!limited!to!evidence!of!active!
cytomegalovirus,!active!Pneumocystis!carinii,!Aspergillosis,!histoplasmosis!or!atypical!
mycobacterium!infection!within!six!months!of!screening!
17! Any!history!of!tuberculosis!
18! Any!history!of!lymphoproliferative!disease!including!lymphoma,!or!signs!and!symptoms!
suggestive!of!lymphoproliferative!disease,!such!as!lymphadenopathy!or!splenomegaly!
19! Any!organ!transplant,!with!the!exception!of!a!corneal!transplant!undertaken!at!least!three!
months!prior!to!screening!
20! Clinically!significant!substance!abuse!
21! Poor!tolerability!of!venepuncture!or!lack!of!adequate!venous!access!for!study!requirements!
22! Inability!to!complete!bladder!diaries,!questionnaires!or!other!study!documents!
!
!
If!a!patient!withdrew!as!a!result!of!pregnancy,!they!would!continue!to!be!reviewed!
for!the!duration!of!the!pregnancy.!Daval!who!sponsored!the!study,!NRES!and!the!
medical!monitor!would!be!notified.!The!patient’s!General!Practitioner!would!also!be!
informed.!!!
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7.5.6 Discontinuation$of$the$Study$
!
The!Chief!Investigator,!Daval’s!medical!expert,!and!the!independent!medical!monitor!
reviewed!safety!data!throughout!the!study.!Criteria!that!would!have!triggered!a!
review!of!continued!study!activity!included:!(1)!the!occurrence!of!one!or!more!
SUSARs!or!SAEs;!(2)!a!high!frequency!of!AEs!that!individually!may!not!have!been!
significant!but!collectively!raised!concerns!about!safety.!!
!
7.6 Study$design$
!
7.6.1 Summary$of$study$design$
!
The!study!was!a!phase!IIa!randomised,!doubleMblind,!placebo!controlled!crossover!
study!to!determine!the!efficacy!and!safety!of!AIMSPRO®!in!the!treatment!of!OAB!
symptoms!in!patients!with!SPMMS.!This!was!a!proof!of!concept!study.!A!schematic!of!
the!study!design!is!presented!in!Figure$26.!
!
7.6.2 Screening$
!
Patients!who!wished!to!enrol!and!were!provisionally!identified!as!suitable!
participants!were!invited!for!screening.!Screening!processes!were!conducted!up!to!
42!days!prior!to!randomisation!and!initiation!of!the!study.!
!
7.6.3 Study$visits$
!
If!screening!was!successful,!eligible!patients!were!required!to!participate!in!two!
blinded!treatment!phases,!separated!by!a!washout!period.!During!each!of!the!
treatment!phases,!the!patient!would!administer!AIMSPRO®!or!placebo!by!
subcutaneous!injection!in!a!twiceMweekly!dosing!schedule.!Nine!doses!of!would!be!
given!in!each!phase.!!
!
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The!first!two!injections!of!each!treatment!phase!were!administered!under!
supervision!at!the!study!centre.!This!was!to!allow!the!patient!or!their!carers!to!be!
trained!in!injection!technique!and!monitor!for!acute!allergic!reactions.!All!
subsequent!treatments!were!administered!at!home!in!the!morning!on!rising.!The!
final!injection!in!each!phase!was!given!on!the!morning!of!the!last!study!visit!prior!to!
attending!the!study!centre.!Patients!and!their!carers!were!asked!to!keep!a!drug!
administration!log!that!was!collected!at!the!end!of!each!treatment!phase!and!filed!in!
the!CRF.!!
!
At!the!end!of!the!blinded!phase!of!the!study,!patients!were!invited!to!continue!
administering!AIMSPRO®!on!an!openMlabel!basis.!Two!further!study!visits!were!
scheduled!during!this!phase!of!the!study.!During!the!openMlabel!phase,!study!visits!
were!scheduled!to!allow!AIMSPRO®!to!be!injected!on!the!morning!of!the!visit.!!
!
7.6.4 Duration$of$the$study$
!
The!expected!maximum!duration!of!the!study!from!screening!to!the!end!of!blinded!
treatment!was!20!weeks.!The!openMlabel!phase!of!the!study!had!a!maximum!
duration!of!38!weeks.!!
!
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Figure!26!Schematic!of!study!design.!
!
SCREENING$
Informed!consent!
Eligibility!checked!
RUNYIN$
!≤!42!days!
VISIT$1,$DAY$0$
Randomisation!
Baseline!data!
1st!injection!
VISIT$2,$DAY$3$
2nd!injection!
Data!collection!
VISIT$3,$DAY$28$
End!of!treatment!
Data!collection!
Patient!attends!on!
day!of!final!injection!
Group$A!!
AIMSPRO!
Group$B$
Placebo!
Group$A!!
Placebo!
Group$B$
AIMSPRO!
VISIT$4,$DAY$70$
Baseline!data!
1st!injection!
VISIT$5,$DAY$73$
2nd!injection!
Data!collection!
VISIT$6,$DAY$98$
End!of!treatment!
Data!collection!
Patient!attends!on!
day!of!final!injection!
!
WASH$OUT$
!42!days!
OPENYLABEL$
!!
VISIT$7,$WEEK$26$
!Data!collection!
VISIT$8,$WEEK$52$
!Data!collection!
End!of!openMlabel!
extension!
!
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7.7 Investigational$medicinal$product$
!
7.7.1 Production$
!
AIMSPRO®!is!a!polyclonal!hyperimmune!serum!product!supplied!as!a!frozen!liquid!
for!injection!(AIMSPRO®!4.5mg/ml).!!The!drug!is!produced!from!pooled!serum!
obtained!from!goats!raised!and!housed!at!facility!in!Tasmania!(Selborne!Biological!
Services!Pty.!Ltd.).!!The!facility!is!registered!with!the!Therapeutic!Goods!
Administration,!a!division!of!the!Department!of!Health,!Australia.!The!animals!are!
vaccinated!using!a!heat!and!detergent!inactivated!HIV!viral!lysate.!!Serum!is!shipped!
frozen!to!Biotec!Services!International!Ltd.!(Bridgend,!UK)!who!holds!the!MHRA!
‘specials’!manufacturing!licence.!The!product!is!purified,!which!includes!viral!
filtration!at!35!nanometres!and!released!after!sterility!and!endotoxin!testing.!All!
manufacturing!processes!are!conducted!to!GMP!standards.!
!
The!placebo!for!this!study!was!provided!by!Biotec!Ltd!as!4.5%!human!albumin!
(Baxter!Healthcare,!Newbury,!UK)!vialed!in!identical!glass!containers!to!those!in!
which!AIMSPRO®!was!provided.!
!
7.7.2 Storage$and$accountability$
!
AIMSPRO®!must!be!stored!frozen!at!M18°C!or!below.!Daval!transported!the!drug!from!
the!manufacturer!to!study!site!frozen.!Electronic!temperature!monitors!travelled!
with!the!product!at!all!times.!On!arrival!at!the!study!site!the!IMP!was!transferred!to!
a!dedicated!freezer!in!the!hospital!pharmacy!provided!by!Daval.!The!unit!was!subject!
to!24Mhour!temperature!monitoring!and!fitted!with!an!alarm.!!
!
The!IMP!(AIMSPRO®!1ml/placebo)!was!provided!in!packs!of!nine!vials!for!each!
treatment!phase.!The!first!two!doses!of!the!study!drug!were!administered!at!the!
study!site!and!were!dispensed!by!the!clinical!trials!pharmacist!immediately!prior!to!
injection.!They!remained!frozen!on!dry!ice!until!administration.!The!remaining!seven!
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vials!of!frozen!product!were!transported!to!the!patient’s!home!with!a!validated!
electronic!temperature!log.!Marken!Logistics!(London,!UK)!was!responsible!for!the!
distribution!of!IMP!to!patients.!Strict!frozen!conditions!were!maintained!at!all!times!
with!continuous!temperature!monitoring.!On!arrival,!a!box!containing!the!remaining!
seven!vials!of!frozen!product!was!deposited!into!a!desktop!freezer!unit!provided!by!
Daval.!At!the!end!of!each!treatment!phase,!the!box!containing!the!electronic!
temperature!log!and!the!empty!vials!was!collected!and!deposited!at!the!study!site!
before!being!returned!to!Daval.!!
!
7.7.3 Administration$of$the$study$drug$
!
Patients!were!instructed!on!the!handling!and!administration!of!the!IMP!prior!to!
administration!at!home.!The!IMP!was!removed!from!the!freezer!unit!immediately!
prior!to!each!injection.!It!was!thawed!by!rolling!the!vial!between!the!hands.!The!
contents!were!usually!ready!for!administration!after!one!to!two!minutes.!The!liquid!
was!then!drawn!up!and!injected!subMcutaneously.!!The!process!had!to!be!completed!
within!three!minutes!of!removal!of!the!vial!from!the!freezer.!!Any!recognised!
injection!sites!could!be!used!but!rotation!was!recommended.!The!patient!was!
supplied!with!alcohol!skin!swabs,!syringes,!and!a!sharps!box.!
!
Anaphylaxis!has!not!been!reported!in!association!with!AIMSPRO®!administration.!
Nonetheless,!the!first!two!injections!were!administered!under!medical!supervision!at!
the!study!site.!The!clinical!area!was!fitted!with!couches!and!an!emergency!call!
button.!Resuscitation!equipment,!including!emergency!drugs!for!the!treatment!of!
anaphylaxis!were!immediately!accessible!within!the!department.!All!research!staff!
had!resuscitation!training!annually.!
!
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7.7.4 Overdose$
!
The!effects!of!AIMSPRO®!overdose!are!unknown.!The!protocol!made!no!specific!
contingencies!in!this!regard.!Any!such!event!would!have!been!assessed!immediately!
and!reported!to!the!Chief!Investigator,!medical!expert!at!Daval,!and!the!independent!
medical!monitor.!
!
7.8 Randomisation$and$blinding$
!
7.8.1 Randomisation$
!
Enrolled!patients!were!randomised!at!their!first!study!visit!to!one!of!two!treatment!
groups!(AIMSPRO®!or!placebo).!The!randomisation!sequence!was!generated!from!
random!number!tables!by!Datapharm!Australia!(Drummoyne,!Australia)!who!
provided!data!management!support!for!the!study.!The!allocation!sequence!was!sent!
to!Biotec!Services!International!Ltd.!who!manufactured!the!study!medication.!The!
study!packs!were!prepared!in!chronological!order!using!the!study!numbers!001M020!
and!the!random!allocation!table!employed!to!allocate!the!medication!sequence.!
Patients!were!randomised!on!a!1:1!ratio!so!half!of!the!group!started!with!either!the!
active!drug!or!placebo.!!
!
7.8.2 Blinding$
!
This!was!a!doubleMblind!study.!Neither!the!investigators!nor!the!patients!were!aware!
of!treatment!allocation.!The!randomisation!code!was!held!in!a!sealed!envelope!at!
the!offices!of!Verius!Ltd.!(Cambridge,!UK)!who!specialise!in!pharmacovigilance!
services.!The!active!drug!and!placebo!were!identical!in!appearance!and!volume,!and!
were!manufactured!in!identical!vials.!!
!
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7.8.3 Unblinding$
!
An!independent!medical!monitor!at!Verius!was!contactable!24!hours!a!day!by!
telephone.!In!the!event!of!an!emergency!requiring!unblinding,!the!Chief!Investigator!
would!be!contacted!to!manage!the!process.!!
$
7.9 Study$procedures$
!
7.9.1 Time$and$events$schedule$
!
A!time!and!events!schedule!summarising!study!activity!is!presented!in!Table$35.!!
!
7.9.2 Screening$
!
Patients!who!wished!to!participate!were!sent!a!patient!information!sheet!and!then!
contacted!by!phone.!Screening!was!undertaken!from!Day!M42!to!Day!M1.!Written,!
informed!consent!was!taken!and!patients!were!then!assessed!by!Dr!Richard!Orrell,!a!
Consultant!Neurologist!at!the!Royal!Free!Hospital,!to!verify!the!diagnosis!of!SPMMS.!
This!assessment!was!a!protocol!requirement.!A!full!medical!history!and!examination!
were!undertaken!and!serum!samples!sent!for!laboratory!analysis.!Urinalysis!was!
conducted.!Concurrent!medications!and!any!adverse!events!were!recorded.!
Inclusion!and!exclusion!criteria!were!checked!and!the!results!of!laboratory!analyses!
were!reviewed!prior!to!confirming!eligibility.!A!bladder!diary!was!provided!for!
completion!before!the!next!visit.!The!first!study!visit!was!scheduled!pending!
satisfactory!laboratory!screening!results.!!!
!
! ! 257!
Table!35!Time!and!events!schedule.!
!
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7.9.3 Study$visits$
!
7.9.3.1 Visit!1!
!
Visit!1!was!conducted!on!Day!0.!Bladder!diary!data!was!collected!from!the!patient!
and!baseline!bladder!function!was!reviewed.!Eligibility!was!rechecked!and!consent!
confirmed.!Any!changes!to!concurrent!medications!and!the!occurrence!of!any!
adverse!events!were!recorded.!A!physical!examination!was!conducted.!!
The!following!patientMreported!measures!were!used!to!assess!bladder!symptoms,!
general!health!status,!the!impact!of!MS!on!physical!and!psychological!wellbeing,!and!
mobility:!
!
− Whittington!Urgency!score.!
− IMQOL.!
− SFM36.!
− MSISM29.!
− MSWSM12.!
!
The!neurologists!Dr!John!McHugh!and!Dr!Kishore!Kumar!completed!the!following!
assessments!of!general!disability,!ambulation,!cognitive!function,!visual!function!and!
peripheral!nerve!excitability:!
!
− EDSS.!
− MSFC.!
− FarnsworthMMunsell!100!Hue!Colour!Vision!Test.!
− LogMAR!visual!acuity!testing.!!
− Threshold!tracking.!
!
Blood!and!urine!were!sampled!for!safety!evaluations!and!exploratory!analyses.!The!
patient!was!then!administered!the!study!drug!and!injection!technique!was!taught.!
The!patient!was!observed!for!one!hour!to!monitor!for!any!adverse!reaction.!
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After!this!period!of!observation,!further!blood!and!urine!samples!were!taken!for!
exploratory!analyses!only.!Neurological!and!neurophysiological!testing!undertaken!
prior!to!dosing!was!repeated:!
!
− EDSS.!
− MSFC.!
− FarnsworthMMunsell!100!Hue!Colour!Vision!Test.!
− LogMAR!visual!acuity!testing.!!
− Threshold!tracking.!
!
These!repeat!assessments!were!conducted!before!and!after!administration!of!IMP!to!
identify!any!immediate!effects!of!administration!on!the!cytokine!profile!and!
neurological!function.!A!bladder!diary!was!provided!for!completion!before!the!next!
study!visit!and!the!patient!was!asked!to!return!on!Day!3.!
!
7.9.3.2 Visit!2!
!
Visit!2!was!conducted!on!Day!3.!The!completed!bladder!diary!was!collected!from!the!
patient.!Eligibility!was!rechecked!and!consent!confirmed.!Any!changes!to!concurrent!
medications!and!the!occurrence!of!any!adverse!events!were!recorded.!A!physical!
examination!was!conducted.!The!second!dose!of!IMP!was!administered!by!the!
patient!under!the!supervision!of!the!investigator.!Injection!technique!was!checked.!
The!patient!was!observed!for!one!hour!to!monitor!for!any!adverse!reaction.!
Arrangements!were!made!for!the!delivery!of!the!remaining!seven!vials!of!IMP!to!the!
patient’s!residence.!A!bladder!diary!and!a!drug!administration!log!were!provided!for!
completion.!The!patient!was!then!allowed!home!and!asked!to!return!on!Day!28.!
!
! !
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7.9.3.3 Visit!3!
!
Visit!3!was!conducted!on!Day!28.!The!completed!bladder!diary!and!drug!
administration!log!were!collected.!Eligibility!and!consent!were!reviewed!and!any!
changes!to!concurrent!medications!or!adverse!events!were!recorded.!A!physical!
examination!was!undertaken.!Blood!and!urine!were!sampled!for!safety!evaluations!
and!exploratory!analyses.!!
!
The!following!patientMreported!measures!were!used!to!assess!bladder!symptoms,!
general!health!status,!the!impact!of!MS!on!physical!and!psychological!wellbeing,!and!
mobility:!
!
− Whittington!Urgency!score.!
− IMQOL.!
− SFM36.!
− MSISM29.!
− MSWSM12.!
!
The!neurologists!Dr!John!McHugh!and!Dr!Kishore!Kumar!completed!the!following!
neurological!and!neurophysiological!assessments:!!
!
− EDSS.!
− MSFC.!
− FarnsworthMMunsell!100!Hue!Colour!Vision!Test.!
− LogMAR!visual!acuity!testing.!!
− Threshold!tracking.!
!
A!bladder!diary!was!provided!for!completion!before!the!next!study!visit.!
Arrangements!were!made!for!the!next!study!visit!on!Day!70!following!a!sixMweek!
washout!period.!!
!
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7.9.3.4 Visits!4O6!
!
Visits!4M6!in!the!second!blinded!treatment!phase!were!conducted!as!described!for!
visits!1M3!in!the!first!blinded!phase.!Upon!completion!of!the!blinded!phase!at!Visit!6,!
patients!were!invited!to!continue!administering!AIMSPRO®!in!an!openMlabel!
extension.!For!those!patients!who!agreed,!arrangements!were!made!for!the!delivery!
of!the!product!to!the!patient’s!residence.!A!bladder!diary!and!a!drug!administration!
log!were!provided!for!completion.!
!
7.9.3.5 Visits!7O8!(openOlabel!phase)!
!
Visits!7!and!8!of!the!openMlabel!phase!were!scheduled!at!26!and!52!weeks!
respectively.!These!visits!were!conducted!employing!the!same!processes!described!
in!Visit!3!of!the!blinded!phase!of!the!study.!Patients!were!provided!with!supplies!of!
AIMSPRO®!throughout!this!period!by!Daval.!At!52!weeks!no!further!supplies!of!the!
drug!were!made!available!and!participating!patients!left!the!study.!
!
7.10 Clinical$and$laboratory$assessments$
!
7.10.1 Clinical$assessments$
!
The!following!clinical!assessments!were!undertaken!in!accordance!with!protocol:!
!
− Bladder!diary!data:!
Mean!voided!urinary!volume!(2.15)!
Mean!24Fhour!urinary!frequency!(2.15)!
Mean!24Fhour!urinary!incontinence!(2.15)!
!
− Questionnaires,!lower!urinary!tract:!
Whittington!Urgency!Score!(2.14.2)!
IFQOL!(2.14.4)!
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− Questionnaires,!MS!health!status!and!disability:!!
SFF36!(2.16.1)!
MSISF29!(2.16.2)!
MSWSF12!(2.16.3)!
EDSS!(2.16.4)!
!
− Neurological!assessments:!
MSFC!(2.16.5)!
FarnsworthFMunsell!100!Hue!Colour!Vision!Test!(2.16.6)!
LogMAR!visual!acuity!testing!(2.16.7)!
Threshold!tracking!(2.16.8)!
!
7.10.2 Laboratory$assessments$
!
7.10.2.1 Biological!samples!
!
All!patients!provided!a!cleanMcatch!MSU!for!analysis!(2.6.1).!Biological!samples!were!
stored!securely!onMsite!in!the!Department!of!Rheumatology,!Royal!Free!Hospital,!
London!(2.8).!
!
7.10.2.2 Laboratory!analyses!
!
The!following!exploratory!laboratory!analyses!were!conducted!as!per!study!
schedule:!
!
− Urine!sample,!screening!and!safety:!
Urinary!dipstick!testing!(2.13)!
Routine!urine!culture!in!hospital!laboratory!(2.12.2)!
!
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− Urine!sample,!exploratory:!
Urinary!ILF6!expression!(2.10.1)!!
Urinary!ATP!expression!(2.11.1)!
!
− Serum!sample,!screening!and!safety:!
Full!blood!count!(FBC)!
Urea!and!electrolytes!(U&E)!
Liver!function!tests!(LFT)!
Calcium!profile!
Thyroid!function!tests!(TFT)!
Erythrocyte!sedimentation!rate!(ESR)!and!CFreactive!protein!(CRP)!
TFcell!subsets!
Serum!protein!electrophoresis!
Hepatitis!B/C!and!Human!Immunodeficiency!Virus!(HIV)!
!
− Serum!sample,!exploratory:!
Cytokine!analysis!
!
7.11 Adverse$events$
!
Adverse!event!data!were!reported!as!outlined!previously!(2.5).!Dr!Brian!Youl!was!the!
authorised!medical!expert!and!Medical!Director!at!Daval.!Verius!Ltd.!provided!
independent!pharmacovigilance!services!and!medical!monitoring!for!the!study.!!!
!
7.12 Data$management$$
!
7.12.1 Data$protection$
!
The!storage!and!protection!of!studyMspecific!data!was!in!accordance!with!GCP!
guidance!for!data!management!in!clinical!research!(2.3.1).!All!study!documents!were!
kept!in!a!locked,!fireproof!cabinet!in!the!Department!of!Neurophysiology,!Royal!Free!
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Hospital,!London.!Dr!Anthony!Kupelian,!study!investigator,!and!Mrs!Elizabeth!
Denver,!Senior!Clinical!Research!Nurse!at!the!Department!of!Medicine,!held!the!only!
keys.!Access!was!granted!to!study!documentation!for!monitoring!and!audit!purposes!
by!authorised!bodies!only.!
!
7.12.2 Data$monitoring$and$audit$
!
Study!conduct!and!all!associated!documents!were!subject!to!regular!external!
monitoring!and!audit!by!PSR!Group!(Hoofdorp,!Netherlands).!The!study!complied!
with!International!Conference!on!Harmonisation!(ICH)!GCP!standards!(European!
Union!Clinical!Trials!Directive!2001/20/EC).!!
!
7.13 Statistical$methods$and$analysis$
!
7.13.1 Study$population$$
!
Twenty!adult!patients!with!SPMMS!and!OAB!symptoms!who!met!the!eligibility!criteria!
for!inclusion!were!invited!to!participate.!The!efficacy!analyses!were!conducted!on!an!
intention!to!treat!(ITT)!basis.!The!ITT!population!included!all!patients!who!received!
any!study!drug!and!generated!outcome!data!at!one!or!more!subsequent!study!visits.!
Safety!data!were!analysed!from!all!patients!who!received!study!drug.!
!
7.13.2 Sample$size$calculation$
!
Previous!data!from!the!study!of!MS!patients!with!OAB!has!demonstrated!that!a!
clinically!significant!change!in!average!voided!volume!is!60!ml!(sd=90)!(529).!The!
primary!objective!of!the!study!was!to!test!the!null!hypothesis!that!the!mean!
difference!in!average!voided!volume!between!active!treatment!and!placebo!was!
zero.!Given!these!data,!a!sample!size!of!20!subjects!would!provide!80.7%!power!to!
detect!statistically!significant!result!at!the!5%!level!(α=0.05).!
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7.13.3 Statistical$methods$
!
Demographic!and!diseaseMspecific!data!were!summarised!using!standard!descriptive!
statistics.!Continuous!data!were!assessed!for!normality!using!graphical!methods,!
employing!visual!assessment!of!frequency!distributions!and!QMQ!plots.!Appropriate!
measures!of!central!tendency!and!dispersion!were!calculated.!!
!
The!efficacy!analysis!was!conducted!to!compare!the!difference!in!outcome!measures!
during!the!two!treatment!phases.!For!the!first!treatment!phase,!data!from!Visit!1!
and!Visit!3!were!compared.!For!the!second!treatment!phase,!data!from!Visit!4!and!
Visit!6!were!compared.!All!efficacy!measures!were!analysed!within!a!mixed!models!
framework.!The!study!drug!and!treatment!group!were!entered!into!the!model!as!
fixed!effects!whilst!the!voided!volume!at!baseline!in!each!phase!was!entered!as!a!
covariate.!Patients!were!entered!as!random!effects.!Any!interactions!between!the!
study!drug!and!treatment!phase!were!reported.!A!BonferroniMHolm!correction!was!
made!to!account!for!variable!multiplicity!in!the!secondary!and!tertiary!analyses!
(394).!No!corrections!were!made!for!missing!data.!
!
7.13.4 Primary$efficacy$analysis$
!
− Change!in!average!voided!volume.!
!
7.13.5 Secondary$efficacy$analyses$
!
− Change!in!24Mhour!urinary!frequency.!
− Change!in!24Mhour!urinary!incontinence.!
− Change!in!Whittington!Urgency!Score.!!
− Change!in!IMQOL.!
− Change!in!SFM36.!
− Change!in!MSISM29.!
− Change!in!MSWSM12.!
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− Change!in!EDSS.!
− Change!in!MSFC.!
− Change!in!FarnsworthMMunsell!100!Hue!Colour!Vision!Test.!
− Change!in!LogMAR!visual!acuity!testing.!
!
7.13.6 Tertiary$efficacy$analyses$
!
− Change!in!peripheral!nerve!excitability.!
− Change!in!serum!and!urine!biomarkers.!
!
7.13.7 Safety$Analysis$ $
!
Safety!data!were!continually!reviewed!throughout!the!study.!All!adverse!events!
were!reviewed!by!the!Chief!Investigator.!A!safety!monitoring!meeting!was!called!
every!three!months!when!the!trial!was!in!progress.!The!Chief!Investigator,!Daval’s!
medical!expert!and!the!independent!medical!monitor!reviewed!the!data.!Meeting!
outcomes!were!communicated!to!the!study!investigators.!
!
7.13.8 Interim$and$subgroup$efficacy$analyses$
!
No!interim!or!subgroup!efficacy!analyses!were!conducted.!
!
7.13.9 Protocol$deviations$
!
All!protocol!deviations!were!recorded!and!graded!in!the!study!documentation.!!
!
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7.14 Results$
!
Between!April!2010!and!December!2010,!81!patients!underwent!screening.!Twenty!
patients!were!eligible!(F=16;!M=4;!mean!age=50;!sd=9.7)!and!participated!in!the!
study.!The!blinded!phase!of!the!study!was!completed!in!May!2011.!The!majority!of!
patients!were!Caucasian!(n=19)!and!the!mean!BMI!of!participants!was!28!kg!mM2.!!
!
Patients!demonstrated!a!longstanding!history!of!MS!symptoms!(mean!symptom!
duration=18.7!years;!sd=7.8)!and!had!established!secondary!progressive!disease!(SPM
MS!duration=5.7!years;!sd=5.9).!At!baseline,!only!three!patients!had!experienced!a!
relapse!in!the!preceding!12!months.!There!were!no!relapses!in!any!patient!within!six!
months!of!study!participation.!Almost!all!patients!used!walking!aids!(n=18).!
!
Urinary!urgency!symptoms!were!significant!(mean!urgency!score=6.5;!sd=2.6;!range!
3M10).!Patients!demonstrated!reduced!functional!bladder!capacity!(mean!voided!
volume=151!ml;!sd=7.8),!frequent!voiding!(mean!24Mhour!frequency=9.4;!sd=7.8)!
and!incontinence!(mean!daily!incontinence!episodes=!1.7;!sd=2.5).!
!
Gastrointestinal!and!psychiatric!disorders!were!the!two!most!common!comorbidities!
amongst!patients.!Constipation!and!depression!were!reported!most!frequently!
(n=10).!Prior!to!screening,!the!use!of!treatments!to!palliate!OAB!symptoms,!including!
anticholinergic!agents!and!DDAVP,!was!widespread!(n=10).!The!protocol!required!
that!these!medications!were!withdrawn!before!enrolment.!
!
All!randomised!patients!received!at!least!one!dose!of!study!drug!and!submitted!at!
least!one!bladder!diary!after!treatment!with!IMP!was!initiated.!Thus,!20!patients!
were!included!in!the!safety!and!efficacy!analyses.!All!but!one!of!the!randomised!
patients!completed!both!blinded!phases!of!the!study.!The!withdrawal!was!due!to!an!
AE!deemed!unrelated!to!IMP!administration!part!way!through!the!first!treatment!
phase.!!
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There!were!82!protocol!deviations!during!the!blinded!phase!of!the!study,!the!vast!
majority!of!which!were!minor.!In!the!main,!these!deviations!were!the!result!of!
mistimed!or!omitted!assessments!and!laboratory!safety!samples!not!being!
processed.!None!of!these!deviations!had!any!effect!on!the!integrity!of!the!study!data!
or!patient!safety.!Study!drug!compliance!was!100%!during!the!blinded!phase!of!the!
trial.!
!
A!summary!of!the!primary!and!secondary!efficacy!analyses!is!reported!below!(Table$
36).!Treatment!with!AIMSPRO®!was!not!associated!with!a!significant!change!in!the!
primary!outcome!measure!of!mean!voided!volume.!None!of!the!secondary!outcome!
measures!indicated!any!effect!on!lower!urinary!tract!function,!bladder!symptoms,!or!
any!nonMbladder!measures!including!disease!status!or!neurological!functioning.!!
!
TwentyMthree!serum!biomarkers!were!assayed!in!the!tertiary!analysis,!selected!on!
the!basis!of!laboratory!and!preMclinical!investigations!of!AIMSPRO®.!These!included!
hormones,!growth!factors,!cytokines!and!other!regulatory!molecules.!Urinary!ATP!
and!ILM6!expression!were!reported.!These!results!are!tabulated!below!(Table$37).!!
!
After!correction!for!variable!multiplicity,!only!corticotrophin!releasing!hormone!
(CRH)!demonstrated!a!statistically!significant!increase!associated!with!AIMSPRO®!
administration.!Several!other!molecules!also!demonstrated!increased!expression!
including!adrenocorticotrophic!hormone!(ACTH),!βMEndorphins,!metMenkephalin!and!
interleukinM23!(ILM23)!but!none!of!these!met!the!criteria!for!statistical!significance!
after!correction!for!the!familywise!error!rate.!!
!
AIMSPRO®!did!not!have!any!detectable!effects!on!peripheral!nerve!excitability!and!
the!data!are!not!presented.!
!
!
! !
! ! 269!
Table!36!Summary!of!primary!and!secondary!efficacy!analyses.!
!
Primary$outcome$measure$$ Mean$difference$(95%$CI)$ Significance$
Mean!voided!volume!(ml)! 0.1!(M33.2−33.3)!! p=0.99!
!
Secondary$outcome$measures! Mean$difference$(95%$CI)! Significance!
Urinary!frequency!(episodes/24!hrs)! M0.3!(M1.0−0.5)! p=0.51!
Urinary!incontinence!(episodes/24!hrs)$ 0.1!(M0.7−0.9)! p=0.73!
Whittington!Urgency!Score$ 0.0!(M1.2−1.2)! p=0.99!
IMQOL*$ 1.8!(M4.5−8.1)! p=0.57!
MSWSM12$ 4.0!(M6.7−14.8)! p=0.47!
MSFC§$ 0.3!(M0.1−0.6)! p=0.14!
MSISM29!(physical)†$ 0.2!(M6.2−6.6)! p=0.94!
MSISM29!(psychological)†$ 1.3!(M6.3−8.8)! p=0.74!
SFM36!(BP)‡! M8.4!(M22.5−5.7)! p=0.24!
SFM36!(GH)‡! M1.7!(M7.7−4.2)! p=0.58!
SFM36!(MH)‡! M1.7!(M11.9−8.5)! p=0.74!
SFM36!(PF)‡! M0.6!(M6.5−5.3)! p=0.84!
SFM36!(RE)‡! 8.9!(M5.2,!23.0)! p=0.25!
SFM36!(RP)‡! 6.1!(M8.8−21.0)! p=0.43!
SFM36!(SF)‡! M4.8!(M21.1−11.5)! p=0.56!
SFM36!(VT)‡! M2.4!(M8.6,!3.88)! p=0.49!
FarnsworthMMunsell!100!Hue!Test! M11.2!(M33.8−11.4)! p=0.35!
LogMAR!visual!acuity!! M0.1!(M0.2−0.1)! p=0.25!
!
*IOQOL!total!score!presented!–!separate!analysis!of!subscales!(1)!avoidance!&!limiting!behaviour;!
(2)!psychosocial!impact;!and!(3)!social!embarrassment!did!not!alter!the!strength!of!the!findings.!
!
§MSFC!total!score!presented!–!separate!analysis!of!components!(1)!9HPT;!(2)!TWT;!and!(3)!PASAT3!
did!not!alter!the!strength!of!the!findings.!
!
†MSISO29!subscales!(physical!and!psychological!impact)!are!presented!separately!as!using!a!
combined!outcome!score!is!not!recommended.!
!
‡SFO36!domains!presented!individually!as!the!results!cannot!be!presented!with!a!single!summed!
score:!BP=bodily!pain;!GH=general!health;!MH=mental!health;!PF=physical!functioning;!RE=role!
emotional;!RP=role!physical;!SF=social!functioning;!VT=vitality!(higher!scores!indicate!better!
function!in!each!scale).!!
!
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Table!37!Summary!of!tertiary!biomarker!analyses.!
!
Tertiary$biomarker$measures! Mean$difference$(95%$CI)! Significance!
POMC!(ng!mlM1)$ !M0.44!(M0.93−0.05)$ p=0.103$
OPN!(ng!mlM1)! !3.31!(M2.16−8.78)! p=0.263!
CRH!(ng!mlM1)! !1.87!(0.87−2.87)! p=0.002!
ACTH!(ng!mlM1)! !0.29!!(0.03−0.55)! p=0.047!
βMEndorphins!(ng!mlM1)! !0.19!(0.07−0.31)! p=0.006!
MetMenkephalin!(ng!mlM1)! !10.36!(4.12−16.60)! p=0.005!
MSH!(ng!mlM1)$ !0.09!(M0.07−0.25)$ p=0.277!
BAFF!(ng!mlM1)! M59.01!(M120.4−2.38)! p=0.082!
FGFβ!(pg!mlM1)$ !5.16!(M5.31−15.63)$ p=0.359$
TGFβ!(pg!mlM1)$ !0.014!(M3.93−3.96)$ p=0.995$
EBNAM1!(U!mlM1)! !25.68!(M48.09−99.45)! p=0.514!
KLK1!(pg!mlM1)! !M7.46!(M36.9−21.98)! p=0.634!
KLK6!(ng!mlM1)! !M4.57!(M8.40−0.74)! p=0.035!
IFNα!(pg!mlM1)! !2.10!(M0.05−4.25)! p=0.062!
ILM1β!(pg!mlM1)! !M0.03!(M2.08−2.02)! p=0.977!
ILM4!(pg!mlM1)$ !1.22!(M1.03−3.47)! p=0.312!
ILM5!(pg!mlM1)! !M3.57!(M11.96−4.82)! p=0.427!
ILM6!(pg!mlM1)! !9.73!(M9.41−28.87)! p=0.344!
ILM10$(pg!mlM1)! !3.13!(M2.62−8.88)! p=0.313!
ILM17!(pg!mlM1)! !0.38!(M0.35−1.11)! p=0.331!
ILM17F!(ng!mlM1)! !144.51!(M27.1−316.08)! p=0.125!
ILM23!(ng!mlM1)! !1.52!(0.60−2.44)! p=0.006!
ILM33!(ng!mlM1)! !3.95!(M0.86−8.75)! p=0.134!
Urinary!ILM6!(pg!mlM1)! M5.27!(M15.85−5.31)! p=0.368!
Urinary!ATP!(nmol!lM1)$ M142.89!(M906.64−618.85)$ p=0.706!
!
POMC!ProFopiomelanocortin;!OPN!Opiomelanocortin;!CRH!Corticotrophic!releasing!hormone;!ACTH!
Adrenocorticotrophic!hormone;!MSH!Melanocyte!stimulating!hormone;!BAFF!BFcell!activating!
factor;!FGFβ!Basic!fibroblast!growth!factor;!TGFβ!Transforming!growth!factor!β;!EBNAO1!EpsteinF
Barr!virus!nuclear!antigen!1;!KLK1!Kallikrein!1;!KLK6!Kallikrein!6;!IFNα!Interferon!α;!ILO1β!Interleukin!
1β;!ILO4!Interleukin!4;!ILO5!Interleukin!5;!ILO6!Interleukin!6;!ILO10!Interleukin!10;!ILO17!Interleukin!17;!
ILO17F!Interleukin!17F;!ILO23!Interleukin!23;!ILO33!Interleukin!33;!ATP!Adenosine!triphosphate.!
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Four!patients!reported!an!AE!prior!to!the!administration!of!any!drug.!Mild!
hypertension!was!noted!in!one!patient!and!another!three!required!treatment!for!UTI!
before!dosing.!FollowMup!cultures!were!performed!in!all!cases.!!One!patient!reported!
pseudomembranous!colitis!after!screening!which!required!the!runMin!to!be!
extended.!Screening!processes!were!repeated!prior!to!study!entry.!
!
TreatmentMemergent!AEs!affected!threeMquarters!of!the!patients.!Twelve!patients!
reported!at!least!one!AE!during!treatment!with!AIMSPRO®!and!eight!patients!
reported!at!least!one!AE!whilst!administering!placebo.!Injection!site!reactions!were!
the!most!common!AE!associated!with!AIMSPRO®!treatment!(n=9).!Transient!
elevations!in!transaminases!(n=2),!pain!(n=1)!and!MS!relapse!(n=1)!were!also!
reported.!During!placebo!administration,!UTI!(n=3)!and!rhinitis!(n=2)!were!the!most!
commonly!reported!AEs.!Adverse!events!that!were!considered!by!the!investigator!to!
be!related!to!IMP!use!are!tabulated!below!(Table$38).!One!patient!withdrew!from!
the!trial!due!to!general!bodily!pain!whilst!administering!AIMSPRO®.!There!were!no!
SAEs.!
!
Nineteen!patients!who!completed!the!blinded!phase!of!the!study!were!invited!to!
continue!using!AIMSPRO®!during!an!open!label!extension!of!the!study.!Eighteen!
patients!accepted!this!invitation!and!one!patient!declined!citing!a!lack!of!perceived!
efficacy!in!the!blinded!phase.!Three!of!these!patients!withdrew!prior!to!Visit!7!and!
declined!any!further!assessments.!Of!the!15!patients!who!attended!Visit!7,!seven!did!
not!attend!for!Visit!8.!Six!of!these!patients!withdrew!citing!lack!of!efficacy!and!did!
not!wish!to!attend!for!any!further!assessments.!One!patient!was!lost!to!followMup.!
The!flow!of!participants!through!the!study!is!summarised!below!(Figure$27).!
!
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Table!38!TreatmentFemergent!adverse!events!considered!related!to!study!drug!
administration.!
!
TreatmentYemergent$AEs*$ AIMSPRO®$(%)$ Placebo$(%)$
All$AEs$ 12$(60)$ 3$(15)$
Injection$site$reactions/general$disorders! 10$(50)$ 0$(0)!
Injection!site!erythema$ 6!(30)! 0!(0)!
Injection!site!inflammation$ 1!(5)! 0!(0)!
Injection!site!urticaria$ 1!(5)! 0!(0)!
Injection!site!eczema$ 1!(5)! 0!(0)!
Pain$ 1!(5)! 0!(0)!
Central$nervous$system$disorders$ 1$(5)$ 0$(0)$
MS!relapse! 1!(5)! 0!(0)!
Cardiovascular$disorders$ 1$(5)$ 0$(0)!
Hypertension! 1!(5)! 0!(0)!
Laboratory$and$clinical$assessment$ 2$(10)$ 2$(10)$
Elevated!serum!creatinine! 0!(0)! 1!(5)!
Elevated!serum!transaminases! 2!(10)! 0!(0)!
Elevated!body!mass! 0!(0)! 1!(5)!
!
*AE=adverse!event;!Causation!defined!as!‘possibly’,!probably’!or!‘definitely’!related!to!IMP!use.!!
!
!
In!the!openMlabel!phase,!median!exposure!to!AIMSPRO®!was!105!days!(range!17M343!
days).!TreatmentMemergent!AEs!affected!half!of!participating!patients.!Most!were!
recognised!symptoms!of!MS!and!very!minor!abnormalities!identified!on!laboratory!
testing.!Two!patients!reported!upper!respiratory!infections!and!two!cultureMpositive!
UTIs!were!treated.!Adverse!events!that!were!classified!as!possibly!related!to!
AIMSPRO®!use!included!one!report!of!optic!neuritis!and!one!episode!of!unscheduled!
vaginal!bleeding.!
!
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!
Figure!27!Flow!of!participants!through!the!study.!
!
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One!SAE!occurred!in!the!openMlabel!extension.!Six!weeks!into!openMlabel!
administration!of!AIMSPRO®,!a!36!year!old!female!patient!was!admitted!to!hospital!
with!worsening!mobility.!This!worsening!in!neurological!function!had!been!slow!and!
in!keeping!with!underlying!disease!progression.!The!patient!was!treated!with!
physiotherapy!and!home!modifications!to!assist!with!mobility!and!safety!were!put!in!
place.!The!patient!was!able!to!return!home!after!a!prolonged!period!of!rehabilitation!
and!formally!withdrew!from!the!study!shortly!after!discharge.!She!cited!lack!of!
efficacy!as!her!reason!for!leaving!the!study.!This!patient!had!experienced!progressive!
problems!with!mobility!that!predated!her!participation!in!the!study.!This!SAE!was!
not!classified!as!related!to!the!study!drug.!
!
High!rates!of!attrition!were!observed!during!the!open!label!phase!of!treatment!and!
almost!twoMthirds!of!patients!did!not!complete!the!study.!All!patients!who!contacted!
the!investigators!prior!to!leaving!the!study!cited!a!lack!of!efficacy!as!their!reason!for!
withdrawal.!Nonetheless,!AIMSPRO®!appeared!to!be!safe!during!extended!
administration!amongst!this!cohort!of!patients.!!
!
!
!
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7.15 Discussion$
!
Patients!with!SPMMS!often!accumulate!significant!disability!that!might!limit!their!
capacity!to!engage!in!clinical!trials!with!more!demanding!protocols!(536).!Patient!
interest!in!this!study!came!from!across!the!UK,!but!the!visit!schedule!was!deemed!
too!challenging!for!many!potential!participants.!Four!subjects!were!screened!for!
every!patient!successfully!recruited!to!the!study.!The!recruitment!target!of!20!
patients!was!achieved!although!one!patient!did!not!complete!the!blinded!phase!of!
the!trial.!Despite!this!loss,!the!efficacy!analyses!were!conducted!on!an!ITT!population!
of!20!subjects,!as!specified!in!the!study!protocol.!The!safety!population!included!all!
20!patients.!!
!
Protocol!deviations!were!frequent!but!minor!and!there!was!no!expectation!that!they!
would!influence!the!results!of!the!trial.!Most!deviations!related!to!insignificant!
delays!associated!with!the!collection!of!biological!samples,!study!drug!administration!
and!visit!timing.!Study!drug!compliance!was!100%!in!the!blinded!phase!of!the!trial!
and!all!efficacy!outcome!measures!were!met.!Occasionally,!serum!samples!for!safety!
monitoring!were!misplaced!after!being!deposited!in!the!NHS!laboratory!at!the!study!
site!but!such!events!were!infrequent.!!
!
In!the!blinded!phase!of!the!study!and!during!extended!openMlabel!administration,!
AIMSPRO®!appeared!to!be!safe.!Cutaneous!injection!site!reactions!were!
commonplace!but!almost!always!selfMlimiting.!Minor!fluctuations!in!laboratory!
markers!were!observed!in!a!minority!of!patients.!No!specific!intervention!was!
required!and!there!was!no!need!to!interrupt!administration!of!the!study!drug.!One!
patient!relapsed!in!the!openMlabel!phase!having!developed!optic!neuritis.!One!SAE!
was!recorded!in!the!openMlabel!extension,!the!result!of!ongoing!neurological!decline!
noted!prior!to!study!entry.!This!was!not!classified!as!related!to!AIMSPRO®!use.!!
!
During!the!blinded!phase!of!the!study,!the!administration!of!AIMSPRO®!was!not!
associated!with!any!effects!on!bladder!function,!lower!urinary!tract!symptoms!or!
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bladderMrelated!QoL.!None!of!the!secondary!outcome!measures!detected!any!
diseaseMspecific!effects!or!changes!in!general!health!status.!The!tertiary!biomarker!
data!did!identify!an!increase!in!CRH!associated!with!AIMSPRO®!use,!which!is!a!
principal!component!of!the!drug!based!on!laboratory!analysis!(507).!Increases!in!the!
pituitary!hormone!ACTH,!the!endogenous!opioid!peptides!metMenkephalin!and!βM
Endorphin,!and!the!proMinflammatory!cytokine!ILM23!were!noted!but!these!changes!
were!not!found!to!be!statistically!significant!after!correction!for!variable!multiplicity.!
No!changes!in!the!expression!of!urinary!cytokines!were!noted!in!association!with!
AIMSPRO®!administration.!
!
The!endogenous!production!of!ACTH!and!βMEndorphin!from!the!pituitary!might!be!
expected!in!response!to!increased!CRH!levels.!Both!molecules!are!cleavage!products!
of!POMC!(537),!secreted!in!response!to!rising!levels!of!CRH.!Thus,!AIMSPRO®!could!
plausibly!enhance!the!pituitary!production!of!these!peptides.!Adrenocorticotrophic!
hormone!drives!the!production!of!glucocorticoids!that!are!known!to!suppress!the!
immune!response!(509)!and!it!is!a!universal!agonist!of!the!melanocortin!receptor,!
expressed!on!numerous!immune!cells!(538).!The!use!of!ACTH!as!an!immune!
modulator!has!been!specifically!studied!in!relapsing!MS!with!encouraging!results!
(539).!
!
βMEndorphin!is!an!endogenous!opioid!that!is!capable!modulating!the!immune!
response!through!inhibition!of!TMcell!activation!(540).!Whilst!synthesised!through!a!
distinct!pathway,!MetMenkephalin!is!another!opioid!peptide!that!may!have!
immunomodulatory!effects.!In!animal!studies,!metMenkephalin!demonstrates!
phagocyte!and!TMcell!suppression!(541,!542)!and!may!be!able!to!influence!the!HPA!
axis!directly!(543).!
!
In!contrast!to!HPA!peptides!and!metMenkephalin!that!demonstrate!
immunosuppressive!effects,!ILM23!is!recognised!proMinflammatory!cytokine!(544).!
InterleukinM23!has!been!convincingly!implicated!in!the!pathogenesis!of!
autoimmunity!and!linked!to!numerous!human!diseases!including!MS!(545M550).!If!
increased!expression!of!ILM23!associated!with!AIMSPRO®!administration!was!
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detected!in!future!studies,!it!would!difficult!to!reconcile!in!view!of!the!claimed!antiM
inflammatory!effects!of!the!drug!(508).!
!
Whilst!the!openMlabel!phase!of!the!study!generated!additional!safety!data!during!
extended!drug!administration,!no!definitive!conclusions!relating!to!efficacy!can!be!
drawn!from!such!an!analysis.!Whilst!measures!of!bladder!and!neurological!function!
were!collected!during!the!extension!phase,!it!was!made!clear!in!the!study!protocol!
these!data!were!not!to!be!used!as!proof!of!a!treatment!effect.!If!significant!changes!
in!any!of!these!data!were!detected!during!openMlabel!administration,!the!findings!
were!only!to!be!used!to!guide!further!research.!!
!
Amongst!those!patients!who!completed!the!openMlabel!phase,!and!accounting!for!
multiple!testing,!sustained!and!statistically!significant!improvements!were!noted!in!
scores!for!the!psychological!subscale!of!the!MSISM29,!and!the!PASATM3!and!9MHPT!
components!of!the!MSFC.!No!consistent!bladder!effects!were!noted!over!the!course!
of!the!openMlabel!phase.!Nearly!twoMthirds!of!the!patients!who!completed!the!
blinded!phase!of!the!study!withdrew!from!the!openMlabel!phase!of!the!study!prior!to!
the!last!scheduled!visit!at!12!months.!Almost!all!cited!a!lack!of!efficacy!as!their!
reason!for!withdrawal.!The!loss!of!more!than!half!of!the!subjects!in!this!phase!of!the!
study!limit!the!utility!of!these!data!for!shaping!future!research.!
!
The!PASATM3!and!9MHPT!components!of!the!MSFC!are!sensitive!to!‘practice!effects’!
which!describe!increased!performance!in!the!completion!of!a!task!related!to!
habituation!rather!the!influence!of!an!intervention!that!is!being!tested!(such!as!a!
study!drug).!Practice!effects!associated!with!the!PASATM3!and!9MHPT!have!been!
reported!to!persist!at!testing!intervals!of!up!to!three!months!(551,!552).!Whilst!the!
first!openMlabel!visit!was!only!three!months!after!the!last!visit!of!the!blinded!phase,!
the!final!visit!in!the!openMlabel!phase!was!conducted!six!months!after!the!previous!
visit.!Whether!a!practice!effect!for!these!measures!could!be!sustained!over!this!
period!is!not!known.!
!
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Whilst!no!changes!in!physical!functioning!were!detected!in!the!physical!domain!of!
the!MSISM29!questionnaire,!sustained!and!significant!improvements!in!the!
psychological!subscale!of!this!measure!were!noted!amongst!patients!who!completed!
the!openMlabel!phase.!The!psychological!subscale!of!the!MSISM29!includes!nine!items!
that!include!an!assessment!of!anxiety,!worry,!confidence!and!depression!(302).!It!is!
plausible!that!the!psychological!impact!of!medicating!with!AIMSPRO®!in!the!openM
label!phase!could!have!conferred!improvements!in!MSISM29!psychological!responses!
through!mechanisms!independent!of!a!direct!effect!on!the!underlying!disease!
process.!
!
Much!has!been!written!in!the!press!and!social!media!relating!to!the!perceived!
benefits!of!AIMSPRO®.!When!interest!in!AIMSPRO®!was!perhaps!at!its!greatest,!
patients!delivered!a!petition!to!Downing!Street!containing!tens!of!thousands!of!
signatures!calling!for!NHS!backing!of!the!drug!(553).!The!impact!of!this!media!
coverage!and!the!perceived!benefits!of!the!drug!cannot!be!dismissed.!It!has!been!
demonstrated!that!the!magnitude!of!a!placebo!effect!can!be!increased!or!decreased!
by!modifying!patient!expectations!(554).!
!
The!selection!of!threshold!tracking!as!an!exploratory!measure!of!nerve!function!in!
this!study!could!be!questioned.!Threshold!tracking!is!conducted!on!peripheral!nerves!
(312)!whilst!MS!is!a!disorder!of!the!central!nervous!system.!Visual!evoked!potentials!
(VEP)!are!an!established!method!to!assess!the!functional!integrity!of!visual!pathways!
in!the!brain!and!they!are!widely!employed!in!the!diagnosis!of!MS!(535).!The!use!of!
VEPs!might!seem!a!more!appropriate!method!of!studying!nerve!function!in!patients!
with!MS,!as!MS!does!not!affect!peripheral!nerves.!!
!
The!selection!of!peripheral!nerve!threshold!tracking!as!a!means!of!investigating!
axonal!function!after!AIMSPRO®!administration!was!made!on!the!basis!of!the!
proposed!neurophysiological!effects!of!the!drug.!Initial!observations!suggested!that!
the!administration!of!AIMSPRO®!was!associated!with!a!reduction!in!the!triggering!
voltages!of!sodium!channels!in!nerves!and!a!prolongation!of!channel!opening!(510,!
511).!Whilst!threshold!tracking!does!not!test!central!nervous!system!function!
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directly,!any!effects!mediated!by!the!drug!on!peripheral!nerve!sodium!channel!
function!would!be!expected!to!be!manifest!by!nerves!in!the!CNS.!No!such!effects!
were!detected!after!AIMSPRO®!administration!under!doubleMblind!conditions.!
!
Prior!to!the!inception!of!this!study,!there!was!great!censure!of!Daval!in!the!MS!
community.!This!related!not!only!to!their!alleged!conduct!and!perceived!exploitation!
of!patients,!but!their!handling!of!previous!studies!of!AIMSPRO®.!The!prospect!of!
another!clinical!trial!of!AIMSPRO®!was!eschewed!by!many!in!the!MS!community,!
although!efficacy!data!were!required!to!guide!clinicians!and!patients.!During!this!
period,!AIMSPRO®!continued!to!be!prescribed!to!patients!and!Daval!attributed!the!
collapse!of!the!London!study!to!failures!on!the!part!of!the!investigators.!
!
The!randomised!phase!of!this!trial!took!12!months!to!complete.!The!study!
demonstrated!that!a!crossover!design,!powered!on!a!clinically!relevant!effect!size,!
was!able!to!provide!a!conclusive!result!whilst!inflicting!much!lower!costs!than!a!
traditional!parallel!group!RCT.!By!contrast,!the!administrative!and!bureaucratic!
conflict!encountered!during!the!development!phase!of!this!project!took!years!to!
overcome.!The!Research!Governance!Framework!in!the!UK!provides!clear!guidance!
relating!to!the!legal!duties!of!sponsors!and!investigators!in!research!studies.!The!
successful!completion!of!the!study!provides!reassurance!that!these!mechanisms!
should!be!trusted!to!protect!the!interests!of!all!parties!in!clinical!research.!!
!
Access!to!the!internet!can!be!extremely!helpful!for!those!affected!by!disability!(555).!
It!allows!patients!to!connect!to!provide!support!and!information!to!one!another,!and!
internet!forums!provide!opportunities!for!group!discussion!and!debate.!This!can!be!a!
vital!resource!for!many!patients,!especially!those!who!may!be!isolated!as!a!result!of!
physical!and!geographical!constraints.!Whilst!patients!may!benefit!from!enhanced!
access!to!information!afforded!by!the!internet,!its!impact!is!not!universally!positive.!
A!recent!paper!has!highlighted!the!dangers!of!research!findings!being!propagated!
through!a!media!disconnected!from!the!scientific!community!(556).!The!authors!
discuss!the!emergence!of!chronic!cerebrospinal!venous!insufficiency!(CCSVI)!as!a!
putative!cause!of!MS,!although!the!analysis!is!relevant!to!any!treatment!that!has!
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been!promoted!through!the!media,!particularly!social,!without!good!evidence!of!
safety!and!efficacy.!There!has!never!been!a!greater!need!for!clinicians!and!scientists!
to!engage!with!the!public!on!these!issues.!
!
AIMSPRO®!continues!to!be!provided!to!patients!on!a!named!basis!in!the!UK!through!
its!registration!as!a!‘special’!with!the!MHRA.!In!other!countries,!‘expanded!access’!
programmes!permit!provision!to!patients!where!clinical!need!cannot!be!met!by!a!
licenced!product.!Whilst!responsibility!for!the!provision!of!unlicenced!medications!in!
these!programmes!is!taken!by!the!prescribing!clinician,!regulatory!requirements!vary!
considerably.!In!the!UK,!clinicians!must!maintain!prescribing!records!and!report!any!
adverse!events!to!the!MHRA,!although!in!some!member!states,!no!legislation!is!in!
place!(512,!513).!The!MHRA!requires!these!medicines!to!be!manufactured!in!
accordance!with!GMP!standards!but!there!is!no!requirement!for!safety!or!efficacy!
data,!or!ethical!review!(557).!This!is!the!case!in!most!European!states!(513).!
!
The!administration!of!AIMSPRO®!twice!weekly!for!four!weeks!was!not!associated!
with!any!detectable!effect!on!lower!urinary!tract!function!amongst!patients!with!SPM
MS!and!OAB!symptoms.!No!diseaseMspecific!effects!were!identified!amongst!the!
secondary!outcome!measures!but!only!an!extended!RCT!of!AIMSPRO®!would!reliably!
determine!whether!longMterm!use!might!confer!benefit.!A!recent!RCT!of!AIMSPRO®!
in!the!treatment!of!systemic!sclerosis,!a!multisystem!autoimmune!disorder,!was!
recently!completed!in!the!UK.!The!trial!demonstrated!that!whilst!AIMSPRO®!appears!
to!be!safe,!there!was!no!concrete!evidence!of!therapeutic!effect,!although!a!nonM
significant!trend!towards!improvement!was!noted!(558).!!
!
Whilst!this!study!was!opposed!in!some!quarters,!the!MS!Society!supported!the!
efforts!of!Professor!MaloneMLee!to!complete!the!study.!They!recognised!the!
importance!of!clinical!trial!data!in!dealing!with!the!ongoing!controversy!surrounding!
AIMSPRO®.!The!data!generated!from!this!study!provide!no!evidence!that!shortMterm!
use!of!the!drug!has!any!beneficial!effects.!
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8 General$discussion$and$conclusion$
! $
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8.1 Background$
!
Lower!urinary!tract!symptoms!are!almost!ubiquitous!in!patients!with!a!longstanding!
diagnosis!of!MS.!Their!impact!is!comparable!to!loss!of!mobility!(54)!and!for!some!
patients!urinary!symptoms!are!the!most!oppressive!element!of!their!disease.!Chronic!
LUTS!are!compounded!by!urinary!infections!that!are!frequently!recurrent!(55)!and!
aggravated!by!high!rates!of!catheter!use!(433).!The!results!of!this!interaction!are!not!
selfMlimiting.!Urinary!tract!infection!exacerbates!existing!LUTS!and!has!been!
implicated!in!functional!deterioration!and!relapse!(171,!173,!174).!Overactive!
bladder!symptoms!are!the!most!prevalent!and!disruptive!LUTS!amongst!patients!
(55).!!
!
Serious!concerns!have!been!raised!over!the!performance!of!diagnostic!tests!
commonly!used!to!exclude!UTI!(187M192,!205M208).!This!is!particularly!relevant!to!
patients!with!MS.!Emerging!data!also!question!whether!undisclosed!infection!may!
generate!OAB!symptoms!(250,!259M261,!263,!264,!271,!273).!!
!
This!study!evaluated!the!performance!of!current!tests!used!to!diagnose!UTI!in!
patients!with!chronic!urinary!symptoms.!Controlled!data!were!gathered!to!
determine!whether!patients!with!MS!and!OAB!symptoms!demonstrate!evidence!of!
urinary!infection!and!inflammation!dismissed!by!routine!testing.!The!relationship!
between!bacterial!infection,!urinary!inflammation!and!OAB!symptoms!was!also!
explored.!The!opportunity!to!test!a!novel!treatment!for!OAB!symptoms!associated!
with!MS!arose!and!this!prospect!was!grasped.!
!
8.2 Limitations$and$weaknesses$
!
Patients!with!nonMneurogenic!LUTS,!rather!than!patients!with!MS,!were!recruited!to!
evaluate!the!diagnostic!accuracy!of!surrogate!markers!of!UTI.!The!volume!of!
participants!required!to!satisfy!the!sample!size!calculation!precluded!the!exclusive!
recruitment!of!MS!patients.!The!study!population!demonstrated!LUTS!of!a!similar!
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distribution!and!chronicity!to!those!reported!by!MS!patients.!Nonetheless,!the!
sampling!strategy!could!limit!the!external!validity!of!the!data.!!
!
The!use!of!different!urine!sampling!methods!amongst!patients!and!controls!could!
have!influenced!the!data.!The!use!of!catheter!sampling!in!control!subjects!would!
have!been!unacceptable,!particularly!as!the!data!were!collected!prospectively!over!
multiple!visits.!Despite!the!lengths!taken!to!minimise!contamination!amongst!control!
samples,!the!introduction!of!bias!as!a!result!of!sampling!strategy!cannot!be!
excluded.!The!culture!methods!used!in!this!work!were!directed!at!the!cultivation!of!
aerobic!uropathogens.!Media!and!culture!conditions!to!detect!fastidious!and!
anaerobic!organisms!were!not!used!and!this!may!have!influenced!the!findings.!
!
An!unplanned!analysis!was!executed!to!determine!the!relationship!between!urinary!
infection!and!symptom!generation!from!the!longitudinal!data.!The!data!model!
specified!in!the!study!protocol!was!abandoned!after!statistical!assumptions!were!
violated!precluding!further!interpretation.!The!use!of!alternative!modelling!
strategies!was!limited!to!constrain!the!impact!of!multiplicity.!Nonetheless,!it!is!
possible!that!this!deviation!could!have!influenced!the!results.!!
!
8.3 Diagnostic$testing$for$UTI$
!
Existing!evidence!suggests!that!current!diagnostic!tests!for!UTI!are!inadequate.!The!
problems!affect!the!culture!methods!used!to!define!UTI!and!their!surrogate!
measures.!The!culture!criteria!defined!by!Kass!(1957)!fail!to!account!for!spectrum!
bias!and!were!devised!to!detect!infection!in!patients!with!pyelonephritis!(186).!The!
importance!of!polymicrobial!infection!has!also!been!overlooked!(194,!559).!It!is!now!
recognised!that!much!lower!culture!thresholds!should!be!employed!to!detect!acute!
infection!confined!to!the!lower!urinary!tract!(187M192).!These!diagnostic!constructs!
may!not!apply!to!chronic!symptoms!(183)!and!data!relating!to!the!performance!of!
dipstick!testing!and!culture!methods!in!patients!with!chronic!LUTS!are!few!(209M211).!
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National!guidance!for!the!screening!of!UTI!in!MS!recommends!the!dipstick!as!the!
primary!tool!to!exclude!infection!(104,!374).!This!work!provides!evidence!that!the!
performance!of!the!dipstick!and!other!surrogates!of!urinary!infection!in!patients!
with!chronic!LUTS!are!extremely!poor,!even!before!the!controversies!relating!to!
bacterial!culture!are!considered.!The!failure!of!these!tests!could!leave!UTI!untreated,!
mediating!significant!negative!effects!on!lower!urinary!tract!function.!!
!
Whilst!not!the!focus!of!this!work,!infection!has!been!associated!with!neurological!
deterioration!and!relapse!in!MS!(152M154,!156,!171).!Urinary!infection!has!been!
implicated!in!this!interaction!and!UTI!is!frequently!associated!with!hospital!
admission!(156,!171,!173,!174).!The!failure!to!diagnose!and!treat!UTI!in!patients!with!
MS!might!increase!the!risk!of!upper!tract!involvement!and!systemic!infection.!This!
could!have!a!considerable!impact!on!neurological!function!and!even!trigger!relapse.!!
!
8.4 Urinary$infection$and$inflammation$
!
Infection!is!being!disregarded!by!standard!culture!methods!and!the!ecology!of!
urinary!infection!is!being!concealed!through!the!use!of!fixed!diagnostic!thresholds.!
Using!a!new!culture!technique!devised!in!this!centre,!urine!samples!were!subject!to!
much!closer!microbiological!scrutiny!than!current!tests!allow!(266M269).!Evidence!of!
urothelial!inflammation!was!sought!by!quantitative!assessment!of!pyuria!and!urinary!
ILM6.!Experimental!measures!of!urothelial!cell!colonisation!and!distress!were!
explored.!These!data!were!carefully!controlled!and!subjects!were!matched!on!key!
demographic!characteristics.!!
!
When!diagnostic!thresholds!were!abandoned!and!more!sensitive!culture!methods!
employed,!cultures!from!patients!and!controls!demonstrated!distinct!ecology.!Whilst!
quantitative!differences!in!bacterial!growth!were!observed,!differences!in!the!
infecting!taxa!amongst!the!groups!were!striking.!In!the!patient!group,!recognised!
uropathogens!including!E.!coli!and!Enterococcus!spp.!were!isolated.!Amongst!
controls,!S.!agalactaie!was!the!dominant!isolate!in!all!but!one!of!the!positive!
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cultures.!Routine!urine!culture!did!not!detect!these!differences.!These!ecological!
findings!were!associated!with!evidence!of!increased!urothelial!inflammation!
amongst!patients,!implying!that!these!microbes!were!more!than!harmless!
contaminants.!
!
8.5 Infection,$inflammation$and$symptoms$
!
The!proposed!relationship!between!urinary!infection!and!the!generation!of!OAB!
symptoms!has!been!forged!from!crossMsectional!studies.!These!data!were!often!
subject!to!inadequate!matching!of!patients!and!asymptomatic!controls.!Prospective!
data!were!needed!to!test!this!hypothesis!and!the!judicious!selection!of!controls!was!
a!necessity.!An!observational!cohort!study!was!undertaken!to!achieve!these!aims.!
Patients!and!controls!were!matched!for!key!demographic!characteristics!and!
monitored!at!eight!study!visits!over!a!twoMyear!period.!!
!
The!emergence!of!pyuria!was!associated!with!increased!bacterial!colony!counts!and!
increasing!pyuria!expression!was!associated!with!a!commensurate!rise!in!bacterial!
load.!These!findings!were!independent!of!routine!culture!status.!Nonetheless,!the!
interaction!between!pyuria!and!bacteriuria!did!not!appear!to!be!a!simple!reciprocal!
relationship.!These!data!imply!that!once!the!inflammatory!response!is!established,!
escalating!inflammation!is!mediated!by!expanding!bacterial!numbers.!By!contrast,!
significant!bacterial!expansion!may!occur!without!inciting!an!inflammatory!response.!!
!
Quorum!sensing!mechanisms!might!restrain!the!expression!of!virulence!factors!until!
a!critical!biomass!is!reached.!Thus,!bacterial!numbers!may!increase!significantly!
without!an!attack!on!the!host.!The!cell!density!at!which!this!occurs!is!likely!to!vary!
between!genera!and!species.!Asymptomatic!bacteriuria!exemplifies!this!
phenomenon.!Increasing!pyuria!was!associated!elevated!levels!of!urinary!ATP!and!ILM
6,!indicative!of!urothelial!distress!and!inflammation,!although!the!strength!of!these!
relationships!varied.!
!
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Increasing!pyuria!was!associated!with!deterioration!in!urinary!urgency,!frequency!
and!voided!volume.!These!relationships!were!independent!of!routine!culture!status.!
The!estimated!effect!size!for!each!of!these!variables!is!likely!to!be!of!clinical!
relevance!to!patients.!These!controlled,!prospective!data!are!the!first!to!
demonstrate!a!significant!association!between!bacterial!infection,!urothelial!
inflammation!and!the!generation!of!OAB!symptoms.!!
!
Whilst!the!influence!of!neuropathology!on!lower!urinary!tract!function!is!
undisputed,!it!does!not!appear!to!be!the!sole!determinant!of!lower!urinary!tract!
function!in!MS.!The!interaction!between!infection,!inflammation!and!neurological!
damage!on!bladder!function!is!likely!to!be!variable!amongst!patients.!Nonetheless,!
these!data!suggests!that!the!treatment!of!presumed!bacterial!infection!in!the!
presence!of!pyuria!might!confer!significant!symptomatic!benefit.!!
!
8.6 Testing$a$novel$treatment$for$the$overactive$bladder$
!
In!the!development!phase!of!this!proposal,!the!opportunity!to!test!a!novel!therapy!
for!OAB!symptoms!in!MS!patients!presented!itself.!Daval!International,!the!
manufacturer!of!AIMSPRO®,!has!promoted!the!drug!as!a!putative!treatment!for!a!
number!of!autoimmune!and!inflammatory!conditions.!Nonetheless,!the!agent!is!
unlicenced!and!evidence!of!efficacy!is!limited!to!clinical!observations!and!reports!
(275,!514M520).!
!
At!the!time!of!writing,!hundreds!of!patients!with!MS!had!used!the!drug!for!periods!of!
up!to!five!years!(524).!Improvements!in!lower!urinary!tract!function!had!been!
reported!during!AIMSPRO®!administration!and!these!benefits!could!be!seen!very!
soon!after!initiating!treatment!(514).!AIMSPRO®!is!claimed!to!have!
immunomodulatory!effects!and!a!drug!that!could!palliate!LUTS!by!such!a!mechanism!
would!be!apposite!to!the!central!hypothesis!of!this!work.!!
!
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The!proposal!was!controversial.!Daval!International,!the!manufacturers!of!
AIMSPRO®,!had!been!accused!of!improper!conduct!relating!to!the!marketing!and!
provision!of!the!drug,!although!these!claims!were!investigated!and!no!charges!were!
made!(522,!523).!Despite!these!concerns,!and!attempts!to!stop!the!study!being!
undertaken,!it!was!completed!successfully.!The!crossover!design!used!in!the!trial!
generated!an!unequivocal!result!without!the!need!for!a!larger!parallelMgroup!trial.!
Such!studies!are!financially!prohibitive!for!smaller!biotechnology!companies!and!may!
restrain!the!development!of!new!candidate!drug!therapies.!
!
The!use!of!AIMSPRO®!for!four!weeks!was!not!associated!with!any!improvements!in!
lower!urinary!tract!function.!There!were!no!detectable!changes!in!neurological!
status!or!neurophysiological!parameters!in!the!blinded!phase!of!the!trial.!Only!an!
extended!study!of!AIMSPRO®!could!reliably!determine!whether!longMterm!use!of!the!
agent!might!confer!benefit!for!patients!with!SPMMS.!A!recently!reported!RCT!of!
AIMSPRO®!in!the!treatment!of!systemic!sclerosis!failed!to!demonstrate!efficacy!after!
six!months!of!treatment,!although!there!was!a!trend!towards!improvement!in!the!
primary!outcome!measure!and!drug!appeared!to!be!safe!(558).!!
!
8.7 Future$work$
!!
Our!approach!to!the!diagnosis!of!UTI!needs!to!be!revised!and!the!disease!should!no!
longer!be!viewed!in!binary!terms.!Rather!than!pursuing!new!diagnostics!to!define!
the!presence!or!absence!of!the!condition,!we!should!seek!to!develop!models!that!
identify!those!patients!most!likely!to!benefit!from!treatment.!This!will!rely!on!a!fuller!
description!of!the!interaction!between!bacteria!and!host.!Studies!to!explore!the!
prevalence!of!atypical!bacterial!infection!in!these!patients!would!complement!this!
work.!The!longitudinal!data!derived!from!this!study!indicate!that!patients!with!MS!
and!OAB!symptoms!who!demonstrate!pyuria!might!benefit!from!antibiotic!
treatment.!Intervention!studies!are!now!required!to!demonstrate!that!antibiotic!
therapy!is!effective!in!palliating!symptoms!and!determine!how!such!treatment!is!
best!delivered.!!
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Existing!data!suggest!that!UTI!associated!with!fever!may!be!associated!with!relapse.!
Whilst!UTI!without!features!of!systemic!involvement!may!mediate!deterioration!in!
neurological!function,!such!infections!have!not!been!convincingly!implicated!in!
relapse.!More!work!is!needed!to!establish!the!influence!of!urinary!infection!on!the!
disease!in!general.!Whether!apparently!localised!infection!can!influence!the!course!
of!MS!is!not!known!and!studies!that!examine!the!immune!response!to!such!
infections!are!needed.!This!is!particularly!important!in!view!of!the!prevalence!of!
undiagnosed!UTI!amongst!patients.!Whether!the!peripheral!activation!of!TMcells!or!
cytokine!production!in!the!absence!of!systemic!infection!might!drive!neurological!
progression!is!unclear.!
!
This!study!provides!the!first!prospective!data!that!support!a!link!between!bacterial!
infection,!urothelial!inflammation!and!the!generation!of!OAB!symptoms!in!patients!
with!MS.!These!findings!may!also!be!of!relevance!to!patients!with!nonMneurogenic!
lower!urinary!tract!dysfunction.!Future!studies!should!include!this!group.!
!
8.8 Conclusion$
!
This!programme!of!study!was!conceived!to!test!the!hypothesis!that!bacterial!
infection!of!the!lower!urinary!tract!goes!undetected!by!routine!diagnostic!testing!
and!contributes!to!the!generation!of!LUTS!in!patients!with!MS.!
!
The!aims!of!the!study!were!as!follows:!
!
(1)!To!determine!the!diagnostic!performance!of!routine!urinalysis!methods!used!to!
detect!urinary!tract!infection!in!patients!with!chronic!lower!urinary!tract!symptoms.!
!
(2)!To!determine!the!prevalence!of!urinary!tract!infection!and!inflammation!in!
patients!with!multiple!sclerosis!and!overactive!bladder!symptoms,!employing!
sensitive!bacteriological!methods!and!measures!of!the!urothelial!inflammatory!
response.!
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(3)!To!determine!the!relationship!between!bacterial!infection,!urothelial!
inflammation,!manifest!by!pyuria!and!elevated!local!proMinflammatory!cytokines,!
and!lower!urinary!tract!symptoms!in!patients!with!multiple!sclerosis!and!overactive!
bladder!symptoms.!!
!
!(4)!To!test!the!effects!an!immunomodulatory!agent!on!lower!urinary!tract!
functioning!in!patients!with!multiple!sclerosis!and!overactive!bladder!symptoms,!
without!evidence!of!urinary!tract!infection!on!routine!testing.!
!
The!study!aims!were!explored!successfully!and!the!results!support!the!central!
hypothesis!of!this!work.!Urinary!tract!infection!is!dismissed!by!current!diagnostic!
tests!and!infection,!associated!with!urothelial!inflammation,!is!commonplace!
amongst!patients!with!MS.!Inflammation!of!the!lower!urinary!tract,!in!addition!to!
neurological!damage,!appears!to!be!associated!with!the!generation!of!overactive!
bladder!symptoms.!Whilst!antimicrobial!therapy!might!be!a!candidate!treatment!for!
this!condition,!further!study!is!required.!The!immunomodulatory!agent!tested!in!this!
work!did!not!have!any!effect!on!lower!urinary!tract!symptoms!or!any!diseaseMspecific!
outcomes!in!MS.!
!
The!risks!of!UTI!for!patients!with!MS!are!considerable!and!the!initiation!of!ISC!is!
associated!with!a!significant!risk!of!chronic!and!recurrent!infection!(165,!167,!168).!
Current!guidance!recommends!the!initiation!of!ISC!at!low!residual!volumes!in!
asymptomatic!patients!without!any!supportive!evidence!(104).!This!
recommendation!needs!to!be!reconsidered,!as!it!may!be!associated!with!harm.!!!
! $
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